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Abstract
There are few protein-based biomarkers to accurately distinguish between patients with low
risk prostate cancer from those with high risk disease in a non-invasive manner. Prostate
specific antigen (PSA) is used for clinical follow-up of prostate cancer; however, it is not
effective as a screening tool. As a result, many men with non-life threatening disease having
to undergo unnecessary and painful biopsies. Therefore, there is a dire need for minimally
invasive platforms for monitoring patients with clinically significant prostate cancer. Prostate
cell microparticles (PCMPs) released by prostate epithelial cells into plasma are a potential
source of biomarkers specific for prostate cancer. I undertook a translational prostate cancer
research project to detect biomarkers expressed in PCMPs isolated from patient plasmas
representing low and high grade prostate cancer, with the goal to differentiate patients. These
novel biomarkers will offer a non−invasive means to differentiate between these two disease
states.
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Chapter 1
« Introduction»
Extracellular Vesicles
Extracellular vesicles (EVs) are a family of heterogeneous, cell-derived fragments or
vesicles, which can be generated by cell membrane shedding or storage vesicle
exocytosis. EV generation typically occurs following biological processes such as cell
activation and modes of cell death such as necrosis and apoptosis (1). Initially perceived
as cellular by-products or ‘dust’ of insignificant biological importance, recent research
has shed light on the role of EVs as mediators of intercellular communication, blood
coagulation and disease progression. Major sources or contributors of EVs in the blood
are platelets, leukocytes and endothelial cells (2). Secretory glands comprised of
epithelial cells also are a major source of EVs (3), but their contribution to the EV pool in
blood is unclear. Several types of EVs are described throughout the literature (Fig.1);
they are categorized according to their size, contents and mechanism by which they are
released (4). For example, exosomes (30–100 nm) are EVs of cytoplasmic origin,
released or exocytosed into the extracellular environment upon fusion of multivesicular
bodies (MVBs) with the plasma membrane (5). Microparticles (MPs; Fig.1, middle
panel), also known as microvesicles, are larger than exosomes measuring 100–1000 nm,
and are the primary result of membrane blebs released from the surface of cells (1).
Lastly, apoptotic bodies (APBs; Fig. 1, left panel) are larger cell derived vesicles,
measuring up to 4000 nm, and are eponymously generated during cellular apoptosis (6).
Given their origin and release from cells, EVs are commonly endowed with a portion of
membrane proteins, and in some APBs, genetic remnants of the parent cell (4). It is now
generally accepted that EVs, such as platelet MPs, play a significant role in modulating
normal physiological processes, such as coagulation (7) via expression of multifunctional
cellular signaling proteins such as tissue factor (8). However, despite observations of
elevated EVs in cancer patient plasmas (9) and other diseases (10), it has still not been
determined whether they originate from tumors, whether they could serve as a rich
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reservoir of biomarkers for disease detection and the role they play, if any, in disease
progression.

Figure 1. Schematic representation of the biogenesis of different extracellular
vesicles.
The most common populations of extracellular vesicles found in biological fluids (saliva,
plasma, semen, etc.) include apoptotic bodies (APBs, left panel),
microparticles/microvesicles (middle panel), and exosomes (right panel). As an outcome
of their biogenesis during cell apoptosis, APBs package a variety of cellular contents
including DNA, RNA, and signaling molecules. During the process of cell membrane
blebbing, membrane and cytosolic proteins are selectively packaged into
microparticles/microvesicles (middle panel), resulting in the enrichment of specific
proteins from the parent cell. Lastly, exosomes contain proteins that are primarily
incorporated during formation of multivesicular bodies, such as tetraspanins CD9 and
CD63. This figure was adapted from Kooijmans et al. (11).
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Intercellular mode of communication
Heralded as an auxiliary means of signaling across vast cellular distances, the ability of
EVs to transport oncogenic factors and regulatory RNA in a vesicle format has been a
topic of intense debate that requires a rollback in perspective. First, classic examples of
cell-to-cell communication are hormone-based paracrine signaling circuits. As a specific
example, testosterone secreted by the testicles or adrenal glands into the circulation
reaches the prostate to sustain gland viability. Testosterone, primarily in a soluble form,
is an essential growth factor for prostate epithelium and only requires nanogram
quantities to elicit a physiological impact. Upstream of this, an additional paracrine
signaling circuit that relies on a brain–gland axis of communication represents another
complex and sensitive means of cell-to-cell communication that occurs between the
pituitary and testicles, in which luteinizing hormone is released into the circulation to
induce testosterone production by Leydig cells.

In contrast to those classic examples, recent key studies have revealed processes by
which EVs are able to interact with their target microenvironment, delivering various
cargo types and facilitating cell-to-cell communication. As an example, leukocyte EVs
are able to modulate endothelial cell activation by delivering pro-inflammatory agonists
onto endothelial cells, resulting in the release of endothelium-derived cytokines and
surface expression of ICAM-1, which is normally agonist-induced (12). Within an
oncology context, glioblastoma cells have been shown to release EVs that express
oncogenic factors such as EGFRvIII on their surface, impacting adjacent cells through
vesicle–cell interactions (13). This represents the first description of ‘oncosomes’,
wherein EVs that express transforming factors such as EGFRvIII are released from
parental tumor cells via membrane blebs and merge with the plasma membranes of
adjacent glioma cells lacking EGFRvIII receptor, resulting in the activation of
transforming signaling pathways and alteration of EGFRvIII-regulated gene expression
(13). Similarly, Peinado et al. (14) investigated the transfer of MET oncogene from
tumor-derived exosomes to bone marrow progenitor cells, wherein exchange of MET
oncogene induced the formation of a pro-angiogenic bone microenvironment and a premetastatic niche (14). Although both of these lauded studies suggest that EVs containing
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oncogenic factors can accelerate oncogenesis or metastasis, the potency of these tumorderived EVs falls far behind that of classic paracrine signaling mechanisms (pituitaryluteinizing hormone-leydig cells) because of the submilligram quantities needed to elicit
a measurable effect in vivo. Hence, these observations may be overly optimistic given the
field’s lack of knowledge regarding the half-life of tumor-derived EVs and the propensity
of the immune system to also release counteracting measures potentially in the form of
exosomes.

Reports of nucleic acid transport via EVs have been the driving force for heightened
awareness in EV research across many different disciplines. For example, Valadi et
al.(15) recently demonstrated that RNA resident within exosomes derived from mouse
mast cells was transferred to human mast cells, resulting in ectopic expression of mouse
proteins in recipient cells (15). This advancement suggests that EVs are envoys between
cells, able to deliver mRNA that can impact protein production in recipient cells of a
measurable magnitude, akin to a hormone operating at the genetic level. Similarly,
exosomes from colorectal cancer cells determined to be enriched with 15 mRNAs
associated with M-phase processes of the cell cycle were delivered to healthy endothelial
cells in vitro, subsequently stimulating the proliferation of recipient endothelial cells (16).
Although the efficiency of this communication delivery system remains unclear, these
findings suggest that EVs from malignant cells can facilitate the delivery of RNAs that
encode factors responsible for cell proliferation. While it is unlikely that entire mRNA
coding regions are transported via EVs, much smaller miRNA present within EVs are
much more likely to be transferred (15). Studies of miRNA residing within EVs have
dominated the field because of their regulatory nature and robustness against degradation.
miRNAs are a family of small, non-coding RNAs (17–22 nucleotides in length) that
regulate gene expression by degrading target mRNAs and nullifying translation of those
target mRNAs (17). miRNAs can directly contribute to tumorigenesis through
modulation of oncogenic or tumor suppressor pathways by targeting mRNAs of
oncogenes or tumor suppressor genes to alter expression (18).
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Given their impact and contributions to tumorigenesis, miRNA can also be used as
biomarkers to identify patients with aggressive or life-threatening tumors in a noninvasive manner. As one example, Taylor and Gercel-Taylor (19) isolated exosomal
miRNA from serum samples of patients with benign ovarian disease, patients with
adenocarcinoma of the ovary and healthy volunteers to profile stage-specific miRNAbased biomarkers. The amount of total miRNA was significantly elevated in
adenocarcinoma patients compared with patients with benign growth, and with minimal
exosomal miRNA detected in healthy controls. The diversity or levels of most miRNAs
was not significantly different between patients with early vs late-stage ovarian cancers,
but expression profiles of exosomal and tumor cell-derived miRNAs were similar (19). In
parallel, biomarker development for lung cancer has also resulted in a panel of miRNAs
(20) validated as biomarkers for diagnosis and prognosis for this disease. As described
previously in ovarian cancer patients, the total amount of exosomal miRNA was also
elevated in patients with lung adenocarcinoma and low or undetectable in control
samples. Most importantly, no significant differences were found when comparing
miRNAs derived from circulating exosomes and miRNAs derived from lung tumors,
indicating that exosomal miRNAs reflect the genomic identity of the tumor and can be
used as a potential blood-based marker for lung adenocarcinoma. Hence, EVs derived
from malignant cells may act as a system of miRNA transport to distant cells and used as
a novel biomarker platform for cancer progression.

EVs generated by breast cancer cells have also been implicated in de novo miRNA
processing and biogenesis due to the presence of Dicer, AGO2 and TRBP proteins within
purified EVs (21). Overlooked in this same study is the contribution of EVs generated by
other sources (endothelial, leukocyte and so on) that are present in the bloodstream with
unknown miRNA content. If in fact miRNA biogenesis is exclusive to breast or breast
cancer cells, this mechanism is unclear and conveniently specific to these sites and
ultimately may not be applicable to prostate cells because these proteins are not present in
prostasomes generated by the prostate (22). Studies like these continue to fall short in
determining whether EV preparations are free of any plasma proteins, which could
represent a source of the Dicer, AGO2 and TRBP detected. Currently, these studies
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dominate currently published reports, lacking sufficient attention to the depletion of
plasma proteins that continue to be present in purified samples. Although the use of
atomic force microscopy is key to these evaluations (23), these reports still fail to
examine the EV preparations at the nanoscale resolution to quantitate soluble protein
contamination, marking these findings as suspect until further validations are performed.

Non-tumor derived EVs of physiological importance
1.3.1 Apoptotic bodies
Damaged, senescent and/or infected cells are often destined to undergo programmed cell
death or apoptosis (Note to Sabine: some infections are lytic and cause necrosis, have to
waffle a bit here or its an overstatement). This process is followed by degradation to
maintain tissue homeostasis and a normal physiologic milieu (24). Although mechanisms
of bleb formation are unclear during apoptosis, cells break apart and form membrane
blebs called APBs, which can contain nucleic acids such as miRNA, mRNA or genomic
DNA (25). Most importantly, APBs also display phosphatidylserine on their surface, an
‘eat-me’ signal for engulfment by phagocytes (for example, macrophages, dendritic cells)
and some fibroblast cells in an immune silent manner (26,27). These APBs play key roles
in adaptive immune responses in which self vs non-self antigens are processed for
subsequent development of T- or B-cell-mediated immune responses, depending on the
ongoing background of immune-based ‘danger signals’ in the body.

In cancer research, APBs have been shown to function as carriers for horizontal transfer
of oncogenic DNA. In one such study, APBs transported oncogenic H-rasV12 and cmyc, to nearby normal mouse embryo fibroblast cells with a p53 knockout background
(28), resulting in tumor-like growth and progression in vitro. Furthermore, phagocytosis
of tumor APBs mediated by immature dendritic cells can induce immune tolerance by
cross-presentation and activation of regulatory T cells (29), revealing a potential
multifunctional role of APBs despite the lack of knowledge in this field.
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1.3.2 Platelet MPs
The discovery of EVs occurred in parallel with the initial studies of blood coagulation,
when researchers observed platelet-like activity in otherwise platelet-free serum samples
(30). However, they were not formally described until the late 1960s, when Peter Wolf
(31) used the term ‘platelet dust’ to describe small, membrane coated fragments he
observed from activated platelets. Wolf considered these vesicles as by-products of
platelet activation during storage, and concluded that coagulation activity in platelet-free
samples was due to the action of ‘platelet dust’. The term ‘platelet dust’ was later
replaced with ‘microparticles’ (32) and ‘exosomes’ (33), in which platelet MPs are
membrane-derived and exosomes being the exocytosed storage granules (alphagranules,
dense granules) of platelets. EVs, either MPs or exosomes, are secreted by platelets (34),
endothelial cells (32) and leukocytes (33), and these types of cell fragments are relatively
abundant in different bodily fluids (2). Through quantification of all circulating MPs in
vivo, it is now understood that platelet EVs are the most abundant types of EVs, when
compared with MPs from other circulating cells (10). Platelet EVs functionally contribute
to coagulation and thrombosis because they are enriched in membrane receptors for key
coagulation factors and prothrombotic proteins. For example, MPs derived from activated
platelets express a high density of prothrombotic proteins on their surface, such as
adhesive receptor P-selectins (8), plasminogen activator inhibitor-1 (PAI-1) and
vitronectin (VN) (35), making thrombi resistant to fibrinolysis. In terms of cancer
research, platelet EVs (MPs and/or exosomes) have been shown to promote tumor cell
invasion in vitro by induction of MMP-2 synthesis in a prostate cell line (Clone-1) (36),
but the impact of platelet MPs on several other prostate cell lines in vitro and in vivo is
still unclear.

1.3.3 Endothelial MPs
Endothelial MPs are membrane-derived particles released upon apoptosis or necrosis,
whereas endothelial EVs are likely exocytosed storage granules of endothelial cells, such
as Weibel–Palade bodies, and are released upon activation by cytokine agents such as
tumor necrosis factor-α (37). For example, in a study where human umbilical vein

8

endothelial cells were incubated with tumor necrosis factor-α and anti-tumor necrosis
factor antibody, it was found that tumor necrosis factor-α elevated endothelial EV
formations by a maximum of 2.5-fold within a 24-hour period (38). Recent studies have
also demonstrated that neoplastic cells induce the release of endothelial EVs, revealing
their potential as a novel biomarker for the detection of cancer and disease progression.
For lung cancer, levels of circulating endothelial EVs were found to be significantly
higher in lung cancer patients than in healthy control subjects suggesting that endothelial
EVs may be involved in endothelial cell proliferation as occurs in angiogenesis (39),
underscoring their pro-angiogenic effect in cancer progression. A subsequent study by
this group examined the potential use of endothelial EVs for predicting 1- year mortality
in patients with end-stage non-small cell lung cancer (34). In accordance with previous
findings, the results of this study revealed that circulating levels of endothelial EVs were
significantly higher in patients with 1-year mortality than in patients within the 1-year
and above mortality category, demonstrating the potential of endothelial EVs as
biomarkers for lung cancer prognosis (34). Yet again, these findings will require further
research to validate endothelial EVs as a prognostic biomarker.

1.3.4 Leukocyte MPs
Leukocyte EVs are released by almost all immune cells when activated by inflammatory
stimuli (40), further activating receptors on other leukocytes, resulting in the secretion of
inflammatory and chemotactic cytokines. In detail, in in vitro co-cultures of leukocyte
EVs with human umbilical vein endothelial cells, leukocyte EVs acted as inflammatory
agonists on endothelial cells which resulted in the release of cytokines interleukin-6 and
interleukin-8, and upregulation of leukocyte-endothelial cell adhesion molecules such as
ICAM-1 (13). These findings suggest that circulating leukocyte EVs can activate a stress
signaling pathway in endothelial cells, leading to an increase in pro-coagulant and proinflammatory activities.

Circulating leukocyte EVs have also been proposed as determinants for cardiovascular
risk factors in asymptomatic subjects. Chironi et al. (37) examined the carotid, abdominal
aorta and femoral arteries to measure levels of circulating MPs in a cohort of
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asymptomatic subjects without previous cardiovascular diseases. Levels of leukocyte
EVs were higher in subjects who carried atherosclerotic plaques in two or three sites
compared with those without plaque at any sites. Therefore, the measurement of
leukocyte EVs has demonstrated biomarker potential in cardiovascular disease in
asymptomatic patients, thus offering encouraging signs of their application in other
disease contexts but none as of yet with oncology although clearly applicable given the
recent advances of immunotherapy for PCa treatment.

Limitation of previous methods of EV characterization and
quantification
Several techniques have been described for the isolation and identification of EVs from
different bodily fluid samples. Minimizing the amount of non-target EVs and other
contaminants is a crucial step towards obtaining a homogenous mixture of EVs.
Scientists have largely relied upon serial centrifugation and ultracentrifugation steps at
increasing speeds and time intervals to isolate EVs from cells, proteins and large cellular
debris (41). However, this method does not guarantee elimination of all non-target
fragments from samples, resulting in enrichment, as opposed to purification of the desired
EV population. This was presented by Mrvar-Brečko et al. (42), who reported that after
several centrifugation steps, samples predominantly contained populations of unwanted
cells mixed with EVs. This method is also time consuming, as it requires repeated
centrifugation steps lasting hours. Immunoaffinity approaches that utilize paramagnetic
beads conjugated with an antibody specific for antigens expressed on the surface of a
target EV are rapid and more target-MP/exosome specific. Beads are mixed with the
sample containing target cell fragments and passed through a column based magnet
separation system (43). The vast majority of non-bead bound cells, non-target MPs and
plasma proteins will pass through the column, whereas antigen-positive EVs bound to
paramagnetic beads become indirectly immobilized to the column via magnets (44). For
purification of prostate-derived EVs, magnetic beads can be conjugated with anti-CD9 or
anti-prostate-specific membrane antigen antibody, and incubated with peripheral blood or
platelet-poor plasma collected from PCa patients (44). This method is rapid and
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customizable, in which the amount of ‘bait’ antibody used can be varied and the number
of times the beads + EVs are washed can vary from two to eight times to fully eliminate
plasma proteins and non-target EVs. Unfortunately, the major limitation of this method is
the lack of bait antibodies available for target EVs and the cost of presently available
ones.

Electron microscopy (EM) is a powerful method to visually characterize cell-derived
vesicles, and scanning EM (SEM) is specifically used to visualize the morphology and
relative size of platelet-derived EVs (31,42). In most cases, SEM can be used to visually
differentiate EVs from erythrocytes and other circulating cells (42). SEM allows certain
analyses that are not possible by other techniques such as determining whether objects
are vesicular or proteinaceous by their ultrastructure; however, it does not quantify the
concentration of vesicles isolated from a sample in a high-throughput manner. SEM also
has significant drawbacks related to preparation of sample(s), with purified EVs
inconsistently being immobilized onto the substrate (silica wafers or mica) for SEM
imaging (32). Atomic force microscopy is another valuable tool that enables the
determination of ultrastructure for all entities (EVs, plasma proteins) at an atomic
resolution (23). Most recently, this technique was used to understand the ultrastructure of
purified platelet MPs (23) and is the only instrument that offers information regarding
protein contamination in purified EV fraction owing to its atomic level of resolution.

To enumerate EVs in any given sample, flow cytometry (FC)techniques would be best
for quantitation of EV subpopulations given the multi-parametric nature of the technique.
Hamilton and colleagues (45) first described the use of FC for detection of cell-derived
vesicles released by human umbilical vein endothelial cells. The reliability of FC to
characterize EVs has substantially improved despite previous ill-informed claims
regarding the inability of optics to accurately acquire scatter of events smaller than 1
micron (μm). The emergence of nanoscale FC has made high-throughput, multiparametric analysis of all events between 110 and 880 nm possible (46) regardless of the
incident wavelength of light used. Using the nanoscale flow cytometer Apogee A50Micro, polystyrene microspheres and silica-based beads can be size-resolved based on
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100 nm increments (47), revealing the potential of this instrumentation to become first in
class for analysis of MPs in complex biological mixtures (48).

A nanoscale based approach to EV purification and
evaluation
In Figure 2, we present an idealized approach to purifying EVs, such as MPs,
microvesicles and exosomes. The sequence of techniques proposed is important because
they will allow the experimenter to evaluate their preparations at a nanoscale resolution
while analyzing each EV as a single discrete event. First, either plasma, serum or urine
can be used as the starting material and submitted to isolation or purification with the
three main techniques. Technique selection for purification is dependent on the
resources, instrumentation and amount of starting material available to the experimenter.
We recommend immunoaffinity based approaches to generate ultra-pure preparations of
antigen specific EVs, such as prostasomes or prostate cell fragments. Immunoaffinitybased approaches also enable the experimenter to ‘wash’ their sample repeatedly prior to
elution, to maximally reduce the presence of non-target EVs and plasma or urine
proteins. The first evaluation step should focus on the enrichment ratio of target EVs vs
non-target EVs. In the case of PCCFs, nanoscale FC is recommended because all EV
events in the sample will be evaluated and the percentage of events that bind the prostate
biomarker can be used to infer enrichment. With exosomes, dynamic light scattering
instruments must be used because nanoscale FC cannot analyze events smaller than 100
nm in diameter. Although this is the ideal instrument for that purpose, it does not inform
the user of the target vs non-target EV ratio unless single fluorescence channel dynamic
light scattering instruments are used. If these instruments are not available, then ELISA
followed by sequential western immunoblotting is recommended. Finally, if an EV
preparation is maximally enriched for target EVs, then the next step is to determine the
extent of plasma protein ‘contamination’ in the sample. This is significant because of the
potential for soluble RNA/DNA and miRNA–protein complexes to be present outside
and alongside the EVs in the preparation. The definitive instrument to determine the
contribution of EVs vs contaminating protein would be atomic force microscopy. Atomic
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force microscopy eliminates all washing and processing of the sample and can be
performed ‘dry’, wherein the solvent is dried off, leaving behind only EVs, ions and
proteins. Owing to its atomic resolution, all events can be volumetrically analyzed, with
events smaller than 100 nm in diameter quantitated and compared with much larger
structures such as MPs. Alternatively, if there are suspicious ultra-structures present in
the sample, SEM can be performed to determine whether the structure is vesicular in
structure, or a protein aggregate. By following this scheme, an experimenter can readily
purify EVs with the full knowledge of the contribution of non-target EVs and
contaminant proteins and nucleic acids present in the purified sample.

13

Figure 2. Summary of purification and evaluation strategy for extracellular vesicles
(EVs) from biological samples.
This scheme can be used to isolate and evaluate EVs from plasma, sera or seminal fluid.
Various techniques can be used to isolate EVs based on size, immunoreactivity to
antibodies, or samples can be sent out for purification by third party vendors. Once
purified, the experimenter may wish to consider the proportion of target EVs to nontarget EVs using western blot, nanoscale flow cytometry, dynamic light scattering or
ELISA. After determining the extent of non-target EVs in the sample, a second set of
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techniques to determine the extent of contamination from non-EV proteins can be
performed using either atomic force microscopy or scanning electron microscopy which
can readily distinguish EVs from protein based on size.
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Current state of prostate cancer diagnosis
Prostate cancer is the most commonly diagnosed visceral cancer among Canadian men.
In 2016 it accounted for 21% of all newly diagnosed cancers, and for ~ 10 % of all
cancer-related deaths among men in Canada (72). This translates to 65 Canadian men
being diagnosed and another 11 dying from PCa every day. The prostate specific antigen
(PSA) testing continues to be heavily relied upon as a monitoring and prognostication
tool; however, it is produced and secreted by both normal prostate epithelium and PCa
into the circulation (4). For this reason, PSA-based screening is discouraged for screening
of PCa because of its low specificity, which means that a high number of PCa cases are
of a low-risk phenotype forcing men to undergo painful and repeated biopsies to ensure
the tumor has not upstaged (73). Most of the time, PSA acts as a "red flag" that causes
considerable anxiety for a patient until the definitive prostate biopsy is taken and
examined by a pathologist (3). Prostate biopsy is the gold standard for diagnosis, as it
provides very important histological information regarding the 5 different patterns of
acinar arrangement and glandular characteristics for grading the tumor with the Gleason
Score (GS) system. Gleason grade 1 represents the most well-differentiated lesion,
whereas Gleason grade 5 represents the most poorly differentiated lesion, and hence a
highly aggressive phenotype of PCa. The most predominant lesion in the specimen also
known as the primary pattern or first number of the GS, and the second most common
pattern in the specimen (the secondary pattern) becomes the second number of the score.
Thus, the Gleason score is the sum of two grades. Only Gleason grade 3, 4, and 5 are
considered histologically and clinically relevant, therefore only a GS of 6 and higher is
considered to be PCa. However, only GS ≤ 7 is regarded as clinically significant prostate
cancer, whereas GS 6 prostate cancer is considered low-risk (73). The recommendation
options for most patients with Gleason Score 6 PCa is active surveillance, which requires
regular PSA testing, physical examination and periodic biopsy to determine if the cancer
has "upstaged" or progressed (74). However, repeated biopsy also submits patients to
potential complications such as hematuria, rectal bleeding, and urinary tract infection
with rare cases leading to mortality (75). Also, PSA levels do not correlate with the
Gleason score of a given cancer (76). Currently, there is a need for new diagnostic tools
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to accurately identify patients with aggressive forms of PCa from those with low-risk
disease.

Prostate MPs
The first studies on prostate EVs in 1977 by Ronquist and Hedström (49) described
vesicles generated within prostate epithelial cells and released via exocytosis into seminal
fluid. These EVs were subsequently termed ‘prostasomes’ (50). In seminal studies
comparing prostasomes from both benign and malignant prostate cells, no significant
differences were reported regarding synthesis and release of these prostate-derived EVs
(51). Although there are few reports describing prostate cell MPs in healthy individuals,
the presence of prostasomes in prostate cancer (PCa) patient plasmas continues to be a
translational cancer research focus (51).

1.7.1 Prostasomes
These vesicles range in size from about 50–500 nm, originate from prostatic epithelial
cells and are present in seminal fluid and post prostatic massage urine (50,51). These EVs
have been shown to protect sperm within the female reproductive system, in which
cytotoxic interactions between prostasomes and natural killer cells significantly reduce
natural killer cells’ activity to prevent immune-mediated sperm destruction (52).
Prostasomes represent a novel cancer biomarker platform because of their release by
malignant prostate cells into seminal fluid and blood (53).
Tavoosidana et al. (54) suggested that the levels of prostasomes reflect disease severity,
based on the detection of prostasomes in blood samples from patients with PCa and high
Gleason score, whereas levels of prostasomes were reduced in samples from patients with
low Gleason score and benign prostatic disease or indolent PCa (54). Despite the small
sample size in this study, it demonstrated that prostasomes can be detected in patient
blood, and have the potential to distinguish aggressive PCa from low-risk or benign
disease (54).
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1.7.2 PCa cell fragments
The potential of prostate cancer cell fragments (PCCFs) to serve as a diagnostic
biomarker platform for PCa is a topic of intense research effort because they are
independent of other serum-based biomarkers currently used for detection of PCa, such
as prostate specific membrane antigen (PSA), which is not specific for PCa (4).

Currently, there is a lack of agreement regarding the best purification strategies for
PCCFs, as well as which biomarkers should be used to characterize PCCFs. Recent
attempts to discover suitable surface markers specific for PCCFs, which relied on
proteomic analysis of isolated PCCFs present in the serum of mice grafted with human
PCa xenografts, identified putative biomarkers such as RAB5A and RAB11A (55). Other
cell-line-dependent studies reveal a higher abundance of proteins such as FASN in cell
fragments derived from PC346C and VcaP cells (4). Many of these reported biomarkers
have not been clinically validated, either in serum or plasma samples, or cross-referenced
with databases, underscoring the need to substantiate biomarkers beyond the initial
discovery phase. An approach that enumerates PCCFs based on a multi-parametric
technique may also improve sensitivity and accuracy if criteria are based on
superimposition of both prostate-specific and cancer-specific biomarkers on the same
PCCF. Clearly, PCCFs present an extracellular source of prostate-specific membrane
antigen reflecting a prostate cell origin (56,57) and should be the initial ‘capture’
biomarker for assaying other cancer-specific biomarkers. Other antigens specific to
prostatic tissue that could potentially be used are STEAP1 (58), STEAP2 (59), and PSCA
(60); however, their utility remains unclear owing to the lack of reagents such as flow
cytometry (FC)-compatible antibodies available for each of these putative prostatespecific biomarkers.

Aside from their putative abundance in patient biofluids, PCCFs, also termed 'large
oncosomes', are also postulated to play a role in disease progression and metastasis (61).
Oncosomes, ranging from 1μm to 10μm in size, can be identified histologically in tumor
tissue sections. Additionally, they exhibit gelatin-degrading proteolytic activity by the
proteases they contain, such as metalloproteinases (MMP9 and MMP2) (61). As these
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proteases are commonly associated with tumor cell invasion, oncosomes may serve to
concentrate proteases that assist tumor cell migration (61). Provided that oncosomes are
stable in the tumor microenvironment and in serum, they in turn could harbor clinically
valuable biomarkers to identify patients with intermediate to high-risk PCa in a
noninvasive blood-based manner.

Currently superseding PCCFs as biomarkers, are circulating tumor cells (CTC),
characterized by co-expression of EpCAM and various cytokeratins in nucleated cells
present in a 7–10 mL blood sample collected from patients. CTCs are thought to be
generated by the release or entry of tumor cells into circulation during the intravasation
step of the metastatic cascade (62). CTC enumeration via the CellSearch Instrument
(63,64) is currently the gold standard for prognostication of patients with metastatic PCa
(65). However, enumeration of CTCs is not a prognostic tool for localized PCa patients
owing to the low CTC counts even in patients undergoing salvage radiation therapy (66).
Despite the low abundance of CTCs in patient blood samples (67), several key studies
have shown that CTC enumeration can distinguish PCa patients from healthy volunteers
(68).

Emerging clinical data suggests that biomarkers derived from plasma exosomes can
similarly differentiate PCa patients exhibiting high and low Gleason scores (GS) from
those with BPH and healthy individuals. Specifically, exosome-associated Survivin is
highly expressed in plasma samples from PCa patients with Gleason score of 6 and 9,
whereas the expression of this protein is significantly lower in BPH and healthy donor
plasmas (69). However, levels of Survivin were not significantly different between the
PCa patients with different GS (6 vs 9), highlighting the need for biomarkers which are
Gleason score-specific. Other EV types such as tumor derived microparticles may offer
an equivalent, if not improved means of prognosticating PCa recurrence given the large
numbers of these submicron entities within patient plasma samples with metastatic
disease (68). Clearly, Coumans and co-workers (68) found that tumor cell MPs and tumor
cell fragments are other types of extracellular vesicle subclasses that can yield important
prognostic information with a large dynamic range, that is highly amenable to blood
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based testing. Various genomic tests for prognostication of early biochemical recurrence
in localized PCa patients have also prompted the notion that these biomarkers in
combination may be present in or on tumor MPs generated by the primary tumor (70).
However, transposing transcriptome-based biomarkers into a protein positive EV-based
format may be challenging given that some of these biomarkers are downregulated or
absent in the target pathology (70).

Alternative, more promising approaches may be based on the presence of microRNAs
(miRNAs) within prostate-derived EVs that are specific to each Gleason grade, or
associated with early biochemical recurrence in patients post prostatectomy or radiation
therapy. Such is the case for miRNA-34a, whose expression within EVs in patient plasma
is predictive of sensitivity to first-line treatment with Docetaxel (71). These studies are
correlative and although suggestive of a pathogenic mechanism, further investigation is
required to conclusively demonstrate compartmentalization of miR-34a within prostate
derived EVs or whether they are derived from other non-cancer sources (71).
Nonetheless, their promise as biomarkers of cancer progression is tantalizing and reflects
a world-wide intensified effort towards understanding EV biogenesis and their ability to
mediate intercellular communication during cancer progression.

Extracellular vesicles such as prostate cancer cell fragments
as a fluid biopsy for prostate cancer
Research to discover new diagnostic biomarkers that could differentiate patients with
indolent, or low-risk PCa, from those with high-risk disease has not significantly
progressed, but the need for a non-invasive test for monitoring PCa patients is of great
clinical value. PCCFs are an attractive biomarker platform for detecting PCa, as these
fragments originate from prostate epithelium or from malignant cells within the primary
tumor and are released into the blood circulation (76). Moreover, it has been previously
shown that significant quantities of PCCFs are detectable in samples from PCa patients,
but are not detected in healthy individuals (61).
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Thesis hypothesis and objectives
The goal of this project is to find biomarkers on the surface of PPCFs that could
differentiate patients with high-grade PCa from those patients with low-grade disease. It
is our hypothesis that PCCFs from patients with low grade prostate cancer (GS 6) will
express different biomarkers than those found on PCCFs from patients with high grade
prostate cancer (GS 8). The following objectives will be pursued in order to reach my
goal.
1. To isolate PCCFs from patient plasmas representing low-grade prostate cancer
(GS6) and MPs from patient plasmas representing high-grade prostate cancer
(GS8) using an immunoaffinity isolation protocol developed by our lab.
2. To assess the enrichment of these isolated PCCFs samples using a nanoscale flow
cytometry and atomic force microscopy
3. To perform proteomic and bioinformatics analysis of isolated PCCFs to identify
biomarkers that differ between GS6 and GS8 patients, which could help to more
accurately diagnose patients with indolent disease from those with an aggressive
form of PCa.
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Chapter 2
Materials and Methods

Patient plasma
Prostate cancer (PCa) patient plasmas samples were attained through the Ontario Institute
for Cancer Research Tumor Bank and the University Health Network Genitourinary
BioBank (Toronto, ON) under Western University Research Ethics Board (REB)
approved Ethics Applications # 103156 and 103409. Only samples from patients with a
minimum of 3 years’ follow-up were included to avoid patients that upstaged/upgraded
during that time. Whole blood was collected into CellSave vacutainers (10mL volume,
Janssen Diagnostics Inc.). To prepare plasma from whole blood for prostate microparticle
analysis, whole blood was collected in K2-EDTA Vacutainers (BD Biosciences Inc.) and
spun at 1500 × g for 10 minutes. The plasma layer was removed, aliquoted and then
stored at -80 ˚C.

Antibodies and isotype controls
Antibodies and isotype controls used in nanoscale flow cytometry and immunoaffinity
isolation techniques have been compiled in Table 2.

Buffers and reagents
Buffers used in the purification of proteins and experiments have been compiled in Table
3.
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Table 1: Summary of antibodies and isotype controls used in this study
Antibody
STEAP1 clone J2D2
(Abcam; CA# ab117454).
PSMA clone 3/E7
(Dr. Philipp Wolf,
University Medical Center
Freiburg, Germany)

Used in
Protein G Immunoisolation/ Nanoscale flow
cytometry/immunostaining

Isotype Control
IgG2b

Magnetic immunoaffinity
isolation/ Nanoscale flow
cytometry/immunostaining

IgG1κ
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Table 2: Summary of buffers used in this study.
Buffer Name

Used in

IP Buffer (ThemoFisher CA#: 28379)

Protein G IP

Elution Buffer, (ThermoFisher, CA#:

Protein G IP

21004)
NuPAGE® Sample Reducing Agent (10X)

Western blot

(Life Technologies, CA#: NP0009)
NuPAGE® LDS Sample Buffer (4X) (Life

Western blot

Technologies, CA#: NP0008)
NuPAGE® MES SDS Running Buffer

Western blot

(20X) (Invitrogen, CA#: NP0002)
Chemiluminescence agent Luminata
Classico Western HRP substrate (EMD
Millipore, CA#: WBLUR0500)

Western blot
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Confirmation of the sizing resolution of the apogee A50micro nanoscale flow cytometer
Silica microspheres (Apogee FlowSystems Inc.) of varying diameters (110 nm, 179 nm,
235 nm, 304 nm, 585 nm, 880 nm, 1300 nm) were analyzed using the A50-Micro
Nanoscale Flow Cytometer (Apogee FlowSystems Inc.). These beads were diluted
1:10000 prior to analysis on the A50-Micro Nanoscale Flow Cytometer.

Immunoaffinity isolation of prostate cancer cell fragments
(PCCFs) from patient plasma with PSMA
To isolate PCCFs from PCa patient plasma (n=10/Gleason score), the Miltenyi Biotec
MidiMACS system was used in which 100µL of plasma was incubated at 4 ºC for 30
minutes with 10 µL of biotinylated anti-PSMA antibody. Subsequently, the plasma was
diluted in 90 µL of dH2O and then incubated with 20 µL of Streptavidin microbeads
(Miltenyi Biotec; CA#130-048-102) for an additional 20 minutes at 4 ºC. The sample was
then diluted in 1 mL of dH2O, passed through a MACS- LS separation column which was
attached to a magnetic field. This step was repeated 3 times (Miltenyi Biotec; CA#130042-401). The column was then removed from the magnetic field and the PSMA positive
PCCFs were eluted twice with 1mL of dH2O. The eluent was then passed through another
magnetic column, and a final elution step was done with a total of 600 µL of dH2O.

Tandem immunoaffinity isolation of PCCFs with Protein G
agarose beads
The Protein G agarose beads were first to STEAP1 antibody in a microcentrifuge tube.
Briefly, 200 µL of Protein G agarose slurry were added to 10 µL of the STEAP1
antibody; the mixed was incubated overnight at 4°C. For the tandem isolation method, 50
µL of Protein G-STEAP1 agarose bead slurry was added to 600 µL of the PCCF samples
previously isolated using the biotinylated-PSMA method, and the reaction was incubated
with gentle mixing for 1 hour at room temperature. To wash the bead-PCCF immune
complex, 100 µL of IP Buffer was added, incubated at room temperature for 5 minutes
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and subsequently centrifuged for 5 minutes at 2500×g; the supernatant was discarded.
The IP Buffer wash step was repeated a total of 3 times. To elute the PCCF’s attached to
the agarose beads, 100 µL of Elution Buffer was added to the beads and incubated for 5
minutes. The tube was centrifuged for 5 minutes at 2500 × g and the supernatant was
collected. This step was repeated a total of 2 times and the two supernatant fractions were
collected and combined. The pH of the eluate was adjusted to physiological pH by adding
~10 µL of a 1M Tris-HCl (pH 7.5-9), per 100 µL of eluate.

EV isolation from patient plasma using exosome isolation
kits
The EV fraction from PCa patient plasma were purified using the following kits:
ExoQuick-TC™ (EQ, System Biosciences Inc.; Mountain View, CA), ExoSpin™ (Cell
Guidance Systems LLC.; Carlsbad, CA), and Total Exosome (Life Technologies Inc.;
Burlington, ON), with some modification to the manufacturer’s recommendations.

2.7.1 ExoQuick-TC™
To prepare the plasma for exosome precipitation, 100 μl of the sample was centrifuged at
3000 × g for 15 minutes. The plasma samples were pre-treated with 1 μl of [500U/mL]
thrombin to make them compatible with ExoQuick exosome precipitation kit. The
mixture was incubated at room temperature for 5 minutes while mixing by gently flicking
the tube, then it was centrifuge in a standard microfuge at 10,000 x g for 5 minutes. The
supernatant was transferred to a new clean tube and treated with 25μl of ExoQuick
reagent to precipitate exosomes, and incubated for 60 minutes at 4°C. The
ExoQuick/biofluid mixture was centrifuged at 1500 × g for 30 minutes, the supernatant
was carefully aspirated, and the pellet was resuspended in 100μl of dH2O and stored at 20°C.
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2.7.2 ExoSpin™
100μl of plasma was centrifuged at 300 × g for 10 minutes to remove cell debris. The
supernatant was transferred to a new microcentrifuge tube and spun at 20,000 × g for 30
minutes. The supernatant was transferred to a new microcentrifuge tube and 50μl of
Buffer A was added and incubated at 4°C for 5 minutes, and then centrifuged at 20,000 x
g for 30 minutes. The supernatant was carefully removed and discarded, and the
exosome-containing pellet was resuspended in 50 μl of dH2O and stored at -20°C. The
supplied column was prepared by spinning it down at 50 x g for 30 seconds to remove
buffer from the top of the column and allowing it to enter the column bed. To wash the
column, 200µl of dH2O were added to the top, and spun down again at 50 x g for 30
seconds. The exosome-containing sample was added to the column and centrifuged at 50
x g for 60 seconds. This step was repeated once more, and the resulting eluate containing
the purified exosomes was stored at -20°C.

2.7.3 Total Exosome™
100μl of plasma was centrifuged at 2000 × g for 20 minutes at room temperature. The
supernatant containing partially clarified plasma was transferred to a new tube without
disturbing the pellet, and centrifuged at 10,000 × g for 20 minutes at room temperature.
The clarified plasma was placed in a new tube without disturbing the pellet, 50 μL of
dH2O was added and mixed thoroughly by vortexing. 30 μL of the Exosome Precipitation
Reagent (from plasma) was added to the sample, mixed by vortexing, and incubated at
room temperature for 10 minutes. The sample was centrifuged at 10,000 × g for 5
minutes at room temperature. The supernatant was removed and discarded and the
remaining exosome pellet was resuspended with 50 μL of dH2O, and stored at -20°C.

Enumerating the PSMA positive populations of PCCFs
To enumerate the populations of PCCFs in patient plasma, a phycoerythrin (PE) labelled
antibody directed against PSMA (PSMA-PE) was incubated with the plasma samples. To
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stain for detection of the PCCFs, 1 μL of the antibody was added to 10 μl of plasma,
incubated in the dark for 30 minutes, then diluted with 290 µL of PBS and analyzed on
the Apogee A50-Micro nanoscale flow cytometer. The negative isotype control mouse
IgG-PE was performed in parallel following the same incubation conditions. Gates for
the PCCF population were established by analyzing the isotype control first, and then
analyzing the antibody labeled samples.

Nanoscale flow cytometric detection of dual positive PCCF
populations
For detection of dual positive PCCF populations, the same protocol as section 2.8 was
followed with some modifications. In brief, 10μl of patient plasma was incubated with
1μl of anti-PSMA-PE and 2 μL of anti-STEAP1-Alexa 647 antibody at room temperature
in the dark for 30 minutes. The negative isotype controls were utilized in parallel
following the same incubation conditions. Samples were diluted with 290 µL of PBS and
analyzed on the Apogee A50-Micro nanoscale flow cytometer. Gates for each
microparticle population were established by analyzing the isotype control first,
modifying the gains for each PMT as necessary, and then analyzing the antibody labeled
samples.

Atomic force microscopy
Exosome suspensions and PCCFs were diluted in dH2O ratios of 1:10, 1:1000, and 1:
10,000. From these diluted samples, a volume of 2 µL was placed and adsorbed to a
freshly cleaved mica coverslip (Ted Pella, Inc.; Redding, California) and dried in an oven
at 60ºC for 5 minutes. Samples were analyzed with the Veeco Dimension 3100 Nanoman
AFM (Veeco Metrology, LLC; Santa Barbara, California) in tapping mode. Topographic
height and phase images were recorded at 256×256 pixels at a scan rate of 1 Hz. Image
processing was performed with Gwyddion Data Processing software, version 2.40
(Department of Nanometrology, Czech Metrology Institute; Brno, Czech Republic).

28

Western blotting
For protein extraction, isolated PCCFs were lysed in a master mix of reducing sample
buffer at a 10X concentration, and LDS sample loading buffer at a 4X concentration.
Samples were boiled for ~10 minutes at 90 ºC. Cellular proteins from LNCaP and PC3M-LN4 cell lysate were also extracted following the previously described steps. To
separate the PCCF and cellular proteins, 10 μg were loaded onto a NuPAGE® Novex®
4-12% Bis-Tris Gels (Invitrogen, CA#: NP0321BOX) and electrophoresed at 200V for 1
hour. Transfer of the gels to a polyvinylidene difluoride transfer membrane (Thermo
Scientific, CA#: 88518) was done at 30V for 1 hour. Blocking of the membrane was done
in 5% powdered milk in TBS-T for 1 hour at room temperature. Membranes were probed
using primary antibody STEA1 or PSMA, overnight in 4°C at a dilution ratio: 1:500, and
then with horseradish peroxidase conjugated-second antibody for 1 hour at room
temperature (Sigma Aldridge, CA#: NXA931-1ML) at a ratio of 1:2000. Protein bands
were detected by using an enhanced chemiluminescence HRP substrate, incubated for 5
minutes at room temperature, and the membrane was developed using the Bio-Rad
ChemiDoc™ MP System (Bio-Rad Laboratories Inc., Hercules, CA).

Mass spectrometry and proteomic analysis of PSMA
isolated samples
This process was contracted out to the Campus Chemical Instrument Center (CCIC) Mass
Spectrometry and Proteomics Facility at The Ohio State University (Arpad Somogyi,
PhD - Associate MS&P Facility Director; http://www.ccic.ohio-state.edu/msp)
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In-solution digestion

2.13.1 List of solution
Solutions prepared for in-solution digestion have been compiled in Table 4.
Table 3: Summary of solutions used for in-solution digestion.
Concentration

200 mM Dithiothreitol (DTT)

Preparation

0.03086 g of DTT in 1000 µL of 100mM
NH4HCO3

1M iodoacetamide

Add 0.037 g of iodoacetamide to 200 µL of
100mM NH4HCO3

Buffer A

25 µL of Acetonitrile + 50 µL 0.1% formic acid +
25 µL ddH2O

Buffer B:

1 µL formic acid + 1000 µL ddH2O

2.13.2 Sample preparation and disulfide reduction
Samples were first prepared by adding 1 uL of a 100mM NH4HCO3. In order to bring
samples to 100 μL, dH2O was added if needed. To reduce the sample, 5 μL of 200mM
DTT were added to the sample, which was subsequently boiled for ten minutes.
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2.13.1 Sulfhydryl alkylation
To alkylate the sample, 4 uL of the iodoacetamide stock was added to the sample and
vortexed, followed by brief centrifugation in a microcentrifuge to get the sample to the
bottom of the tube. The sample was incubated 1 hour at room temperature.

2.13.2 Stopping alkylation
To neutralize the remaining iodoacetamide, 20 μL of DTT stock was added to each
sample, which was then vortexed and incubated at room temperature for 1hour.

2.13.3 Trypsin digest
For trypic digestion, each sample was gently vortexed and trypsin was added at a 1:20
ratio (1mg of trypsin for every 20mg of sample). To allow complete digestion, the sample
was placed in a 37°C water bath overnight.

2.13.4 Sample clean-up
The SPE cartridges (HyperSep™ C18 columns - 50mg resin, Thermofisher CA: #60108390) were prepared by first washing the column 3 times with 1mL of Buffer A, then 3
times with 1 mL Buffer B, eluting the flow through into a waste beaker. Subsequently,
the samples were acidified with 0.2% formic acid and passed over the SPE cartridge
twice. The unbound components were washed off the column with 1 mL of Buffer B 3
times. The peptides were then eluted off of the column with 400 µL of Buffer A. To
reduce the volume of the samples and remove the acetonitrile, samples were concentrated
using a Speed-Vac.
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Mass spectrometry and proteomic analysis of tandem
isolated samples
This process was contracted out to the Biological Mass Spectrometry Laboratory at the
University of Western Ontario (Director: Prof. Gilles A. Lajoie;
http://www.uwo.ca/biochem/bmsl/)
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Chapter 3
« Results»

The A50-micro nanoscale flow cytometer analyzes events
within the submicron size range, and detects PSMA positive
extracellular vesicles
The A50-Micro nanoscale flow cytometer (NFC; Apogee Flow Systems, Hertfordshire,
UK) is reported by the manufacturer to be capable of high-throughput and multiparametric analysis of events between 100-1000 nm, resolving various sizes of
calibration beads based on large angle light scatter (LALS) and small angle light scatter
(SALS). We ran silica beads of various diameters, 110 nm, 179 nm, 235 nm, 304 nm, 585
nm, 880 nm, 1300 nm (Fig. 3A-B), though the A50-Micro NFC. The analysis of these
beads show that the A50-Micro has the ability to analyze events within the submicron
size range, resolving discrete subpopulations when analyzed together.
The corresponding analysis of PCa patient plasma with the A50-Micro nanoscale flow
cytometer (Fig. 3C) demonstrate that when the plasma is incubated with an anti-PSMAPE antibody, a subpopulation of prostate cancer cell fragments (PSMA positive PCCFs)
is observed and determined to be within the 110-304 nm diameter size range (red box).
This population is distinct from other particles in the sample, which are PSMA negative
(blue box), in both size and immunofluorescence. When the isotype control mouse IgG1ƙPE was incubated with PCa patient plasma, a minimal number of events were recorded
(Fig. 3D, red box).
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Figure 3. Nanoscale flow cytometry analysis of sizing beads and PCa patient plasma
measure events within the submicron range.
The Apogee A50-Micro nanoscale flow cytometer is able to readily analyze events within
the submicron range based on the analysis of silica beads of various diameters (A and B).
When patient plasma is incubated with anti-PSMA-PE antibodies, a subpopulation of
PSMA positive PCCFs are observed within the 110-304 nm diameter size range (C).
Isotype control IgG1ƙ-PE incubated with patient plasma does not detect a significant
number of events (D).
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Immunoaffinity isolation using PSMA antibodies enriches
extracellular vesicles from prostate cancer patient plasma
The immunoaffinity method for PCCF isolation (Fig. 4A) utilizes a biotinylated PSMA
antibody and a streptavidin conjugated magnetic bead to separate PSMA positive PCCF’s
from other plasma components, such as cell debris and non-target MP’s. When patient
plasma is incubated with the biotinylated PSMA antibody and streptavidin beads and
subsequently passed through a magnetic field, the magnet attracts the PSMA positive
PCCFs, while other plasma components which are PSMA negative are not retained,
resulting in concentration and recovery of PSMA positive PCCFs.
The enrichment evaluation of immunoaffinity purified PCCFs from patient plasma shows
the relative abundance of PSMA-PE positive PCCF’s (red box) compared to the total
events of other non-target MPs (grey shaded areas) in plasma before PSMA
immunoaffinity isolation (Fig. 4B), within the first elution fraction (Fig. 4C), and within
the second elution fraction (Fig. 4D) from the same plasma sample. The population
events of non-target MP’s and other cell debris is greater in plasma samples before
immunoaffinity purification, when compared to PSMA positive PCCFs. After the first
elution, the non-target MP population is significantly reduced relative to the PSMA
positive PCCFs. After the second elution, a greater reduction of non-target MPs is
observed, and PCCF events. The relative abundance of PSMA positive PCCFs shows the
enrichment of this populations after isolation. In patient plasma (B), PSMA positive
events account for 1.1% of all events. After the last elution fraction (D), 21.5% of the
overall events are PSMA positive PCCFs.
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Figure 4. Working model of biotinylated-PSMA technique enriches PCCFs from
patient plasma and are quantified using nanoscale flow cytometry.
The biotinylated PSMA immunoaffinity method targets PCCFs from prostate cancer
patient plasma that are positive for PSMA, and washes out EVs which do not express
PSMA (A). Enrichment of PCCF populations (red gates) compared to total non-target
EV populations (shaded areas in histoplot) in patient plasma (B), first elution fraction
(C), and second elution fraction (D).
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Atomic force microscopy (AFM) evaluation of controls
shows size distribution of soluble proteins
Standard controls, including bovine serum albumin (BSA) and platelet poor plasma (PPP)
at varying concentrations, were used to help identify protein content in a sample and
measure the height and distribution of contaminating protein in the PCCF preparations.
Atomic force microscopy (AFM) analysis performed at 5 µm ×5 µm and at dilution
factors of 10X (Fig. 5A), 1000X (Fig. 5B), and 100,000X (Fig. 5C), shows the capability
of AFM to measure events in the submicron size. In the images representing both BSA
and PPP (diluted 10X), the samples are dominated by smaller events (̴̴̴̴ 5-10 nanometers
high), which reflects the small monomeric proteins that are abundant in the BSA and PPP
controls. Some larger events, between 30-60 nm in height and ~800nm in diameter may
represent extracellular vesicles in the samples. As samples were further diluted to achieve
lower concentrations of both BSA and PPP (1,000X and 100,000X dilution factors), the
images reveal the magnitude of plasma protein depletion, with a corresponding decrease
in particles visible in the field of view of the AFM. Fig. 5D depicts AFM analysis
performed at 1 µm by 1 µm of both the BSA and PPP samples.
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Figure 5. Atomic force microscopy images of bovine serum albumin and plateletpoor plasma reveal size and distribution of proteins at varying concentrations.
Height channel of AFM images from BSA and PPP reveal the size and distribution of
proteins and other particles in these samples. As expected, diluting the samples reduces
the concentration of particles in the samples, confirming that the detected signal is sample
specific.
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Multimodal characterization of PCCFs isolated using
different techniques reveals that the immunoaffinity method
is the most efficient at eliminating background proteins
Prostate cancer cell fragments from patient plasma were isolated using PSMA
immunoaffinity-based purification and 3 commercially available extracellular vesicle
purification kits. A total of 10 samples per isolation method were submitted to NFC and
AFM; the images in Fig.6 represent the analysis of one sample per isolation method.
Sample purified using the immunoaffinity method (Fig. 6A) show the presence of
extracellular vesicles with a small amount of proteins in the background.
Images of the samples isolated with Total Exosome (Fig. 6B) and Exo Spin (Fig. 6C) kits
show the presence of isolated extracellular vesicles; however, most of the sample is
dominated by co-isolated contaminating protein. The purification of extracellular vesicles
with the Exo Quick kit (Fig. 6D) resulted in the highest concentration of co-isolated
contaminant proteins, as illustrated in the AFM image of this sample.
Flow cytometry analysis of isolated PCCFs depicts the enrichment of PSMA positive
particles (red box) compared to the total amount of other MPs and co-isolated particles
(shaded areas in histoplot). The sample purified by immunoaffinity shows the greatest
reduction of non-target MP’s population relative to the dense population PSMA positive
PCCFs (Fig. 6A). In contrast, the scatterplots representing the three isolation kits contains
a larger population of non-target MP’s (Fig. 6B, C, D). The relative abundance of PSMA
positive PCCFs shows the enrichment of achieved after each isolation method. The
highest percentage of PSMA positive PCCFs was achieved with the immunoaffinity
isolation method (Fig. 6A), with 49.7% of all events being PSMA positive. For the
isolation kits, the overall PSMA events were much lower. Total Exosome (Fig. 6B) had a
relative abundance of 38% PSMA positive events; Exo Spin (Fig. 6D) showed a 30% of
all events were PSMA positive; and lastly the lowest PSMA abundance was from the Exo
Quick kit (Fig. 6C), with 14% of all events being PSMA positive PCCF.
Assessment of PCCF volumetric data shows the differences between the vesicles isolated
using the isolation kits and those isolated with the PSMA immunoaffinity technique (Fig.
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6E). The particles measured were from one individual sample per isolation method, and
one sample of bovine serum albumin (BSA). The BSA volumetric data was used as a
control. Volumetric measurement of EV provide useful information regarding sizing,
with the majority of all objects imaged exhibiting particle volumes below 1.0 x 10 -18 m3;
this is consistent with previous studies of EV volumetric data (23). PCCFs measures from
the PSMA isolation group (Fig. 6E, PMP34) shows to have a mean volume of 1.0 x 10 -19
m3. The mean volume of particles in BSA is below 1.0 x 10 -22 m3, due to the high
quantity of proteins in the sample. From the isolation kits, the volume of particles was
mostly below 1.0 x 10 -20 m3, with many events close to the volume of particles found in
BSA, showing that these kits are co-isolating a high quantity of proteins. Volume of the
particles isolated with PSMA was significantly different than particle volume in BSA and
from Total Exo kit (both P= 0.0001; Kruskal-Wallis Test), but not from Exo Quick and
Exo Spin kits (P= NS; Kruskal-Wallis Test). All volume mesurements obtained from the
exosome kits were not significantly different from particle volume in BSA (P= NS;
Kruskal-Wallis Test).
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Figure 6. Atomic force microscopy and nanoscale flow cytometry reveal differences
in particle size and distribution in PCCF samples obtained using different isolation
methods.
AFM images representing the height and amplitude of isolated EVs demonstrate the
differences in content of extracellular vesicles versus co-isolated contaminant protein and
non-target particles. NFC of all samples also demonstrates the differences between all
methods in depleting ‘noise’ populations (outside red boxes) (A, B, C, D). Volumetric
data of PCCFs isolate with PSMA immunoaffinity and three isolation kits; BSA used as a
control (E). ***P= 0.0001, ****P= 0.0001; Kruskal-Wallis Test.
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Atomic force microscopy resolves three dimensional surface
characteristics of isolated PCCFs
Atomic force microscopy evaluation of PCCFs isolated with the PSMA immunoaffinity
approach detects individual PCCFs measuring ~110nm in height (Fig. 7A). AFM
imaging also shows that the background of the sample contains minimal amounts of coisolated proteins and other EVs from the plasma samples. The height of isolated PCCFs
are within the range previously determined with NFC. I used the Gwyddion software to
analyze the PCCF in the inset, both in 2 and 3 dimensional planes. The 2 dimensional
image of the inset reveals that at a closer magnification (1 µm × 1 µm), the surface of this
individual PCCF contains areas with higher peaks (Fig. 7A-inset). The 3 dimensional
image (Fig. 7B) allows for superior resolution of peaks observed in the previous image.
When one individual peak is measured, it was shown to be ~14 nm in height (Fig. 7C).
These peaks could represent receptors or other membrane associated proteins on the
surface of the PCCFs.
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Figure 7. Atomic force microscopy resolves three-dimensional structures of PCCF
isolated from patient plasma and reveals small peaks in PCCF surface.
AFM images of multiple PCCFs in one sample show their distribution, as well as the
background of the sample to detect co-isolated proteins, which in this case are virtually
depleted (A). Individual PCCFs can be imaged in 2 (inset) and 3 (B) dimensional planes.
A profile of an individual PCCF can be plotted to accurately measure peaks on the
surface of the particle, which may correspond to membrane associated protein (C).
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Mass spectrometry analysis of PSMA-isolated PCCFs
identifies an abundance of albumin and protein peptides
from tissues other than prostate
Prostate cancer cell fragments isolated with the PSMA immunoaffinity method were
submitted for mass spectrometry analysis in order to find proteins which differ from each
Gleason score group (N=2; one sample belonging to Gleason score 6 and one sample to
Gleason score 8). Sample preparation and LC-MS/MS was performed by the Ohio State
University Mass Spectrometry and Proteomics Facility. Consensus lists containing all
protein hits from each of the samples were provided from this analysis (Appendix A and
B).

Analysis revealed a total of 158 proteins identified for the Gleason score 6 sample, and
209 proteins identified for the Gleason score 8 sample. In both types of samples, there
was an abundance of plasma proteins, such as albumin and immunoglobulins. Other
abundant proteins include components of the coagulation and complement cascades,
cytoskeleton-associated proteins, enzymes, and signaling molecules. Keratins and other
skin related proteins were found in abundance in both sets of samples, indicating the
possibility of contamination of the samples. We were not able to find any prostate
specific proteins which we could use as potential biomakers.
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Nanoscale flow cytometry detects STEAP1 positive events in
prostate cancer patient plasma as well as dual positive
PSMA-STEAP1 PCCF events
Analysis of PCa patient plasma with the A50-Micro nanoscale flow cytometer
demonstrates that events in plasma are within the 110-800 nm diameter size range (Fig.
8A), with a large population of ‘noise’ particles which are smaller (red oval). When
analyzing PCa patient plasma samples with the isotype control IgG2b-Alexa647 (Fig. 8B,
red box), a very small number of events were detected by the NFC, allowing us to
determine the placement of gates to identify positive events. When plasma is incubated
with an anti-STEAP1 Alexa647 antibody, a subpopulation of PCCFs which express
STEAP1 is detected within the previously set gate (Fig. 8B, red box). This population is
distinct in both size and immunofluorescence from other particles in the sample (Fig. 8B,
blue box).
The A50-Micro NFC also has the capability to measure events which are positive for two
antibodies. Dual positive assessment of PCa patient plasma shows events which are
recognized by both PSMA-PE and STEAP1-Alexa647 antibodies. Indeed, a large
population of dual positive PCCFs is detected (Fig. 8D, top right quadrant). This
scatterplot also shows the events that are negative for both antibodies (Fig. 8D, bottom
left quadrant).
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Figure 8. Nanoscale flow cytometry reveals the incidence of STEAP1 positive PCCF
events in PCa patient plasma samples, and also detects dual PSMA-STEAP1
positive events in PCa patient plasma samples.
NFC analysis of patient plasma reveals that samples contain EV populations of varying
sizes, as well as a large population of ‘noise’ particles (A). The isotype control allows for
the placement of gates as a threshold for negative events (B). The NFC detects clear
subpopulations of STEAP1 positive (C) as well as dual PSMA-STEAP1 positive (D)
PCCFs.
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Tandem immunoaffinity isolation of PCCFs significantly
reduces non-target MP populations, while maintaining
PSMA+STEAP1 dual events
Tandem immunoaffinity isolation of PCCFs consists of an initial isolation of the
fragments from patient plasma using the biotinylated-PSMA method. A second
immunoisolation technique is then performed, using the STEAP1 antibody (Fig. 9A). In
other words, the PCCFs isolated using the PSMA method are then incubated with the
Protein G-SEAP1 immune complex. In this way, the non-target PCCFs that are STEAP1
negative are washed form the sample, and the PSMA-STEAP1 dual positive PCCFs are
eluted for subsequent analysis.
PCCFs isolated with the tandem immunoaffinity method were evaluated using NFC to
assess the efficiency of this technique at enriching PCCFs populations. Individual
scatterplot for PSMA-PE, STEAP1-Alexa647, and dual positive PCCF events were
measured to determine the number of PCCFs that are recognized by one, or both
antibodies. Individually, the expression of PSMA (Fig. 9B, red gates) and STEAP1 (Fig.
9C, red gates) was detected in a significant number of events in isolated PCCFs.
Correspondingly, a high number of dual-positive events were detected as observed on the
top-right quadrant of the scatterplot, and this was determined to be ~40% of all events
measured (Fig. 9D, top right quadrant). This is an ~11-fold enrichment from the PCCF
population detected in samples of plasma only. The ‘noise’ population, which is negative
for both PSMA and STEAP1, was significantly reduced after tandem isolation (Fig. 9,
bottom left quadrant).
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Figure 9. Nanoscale flow cytometry analysis of tandem immunoaffinity isolated
PCCFs from patient plasma show the enrichment of STEAP1 positive as well as
dual PSMA-STEAP1 positive events.
This method of PCCF isolation utilizes Protein G agarose beads and STEAP1 antibody,
which are incubated with the pooled PCCFs previously isolated with PSMA (A). NFC
analysis shows that this tandem immunoaffinity isolation yields a sample containing
PCCF populations which are positive for PSMA (B) and STEAP1 (C), and a double
positive population of PCCFs which expresses both antigens (D).
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Western blot detection of prostate proteins in prostate cell
lysate and PSMA immuno-purified PCCFs, but not in
tandem isolated PCCF samples
Western blot analysis was performed to measure PSMA and STEAP1 protein expression
in PCCFs isolated using the PSMA technique only, as well as PCCFs isolated using the
tandem technique. Cell lysate from LNCAP and PC-3M-LN4 cells (10 μg) were also
loaded onto gels as controls for PSMA and STEAP1 protein expression (Fig. 10).
Protein bands for STEAP1 are clearly seen in PC-3M-LN4 cell lysate at 47 kDa, which is
the expected molecular mass of STEAP1 (Fig. 10A). In the LNCaP cell lysate, the
STEAP1 protein band is less prominent than in PC3 lysate; however, a faint band is also
detected at 47 kDa (Fig. 10A). PSMA protein bands are clearly seen in PC-3M-LN4 and
LNCaP cell lysate at ~110 kDa.
Samples containing PCCFs isolated using the biotinylated-PSMA technique show the
presence of a ~110 kDa band corresponding to PSMA, and a band at ~47 kDa
corresponding to STEAP1 when ~10μg of protein are also loaded onto the gels (Fig. 10B;
N=5, S1-S5). Both proteins are differentially expressed in individual samples, possibly
due to the high variances in protein content from one sample to another. ß-actin bands
were not detected in these samples.
After tandem isolation, the protein concentration of the PCCF is extremely low and I
could not load 10 μg as done previously. Consequently, I could not perform western blot
analysis to detect PSMA or STEAP1.
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Figure 10. PSMA and STEAP1 protein expression in LNCaP and PC-3M-LN4
prostate cancer cell lines and PCCFs isolated with biotinylated-PSMA method.
Western blot analysis PSMA and STEAP1 protein levels of in LNCaP and PC-3M-LN4
cell lysate (A), as well as in PCCFs isolated using the biotinylated-PSMA
immunoaffinity isolation from 5 different patient plasma samples (B; S1-S5). Neither
PSMA nor STEAP1 were detected in the tandem immunoaffinity isolated samples, likely
because insufficient protein was recovered (data not shown). ß-actin was detected in cell
lysate for LNCaP and PC-3M-LN4; however, it was not detected in both isolated samples
(data not shown).
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Mass spectrometry results of tandem isolated samples reveal
abundance of plasma and cytoskeletal proteins.
To obtain detailed information on the identities of the proteins contained in the plasma
isolated PCCFs, we submitted the samples for LC–MS/MS proteomic analysis. Initial
sample preparation for proteomic analysis was done by in-gel digestion of the samples.
An image of SDS-PAGE gel from one tandem isolated sample (sample ID: PMP-324)
reveals the absence of any visible protein bands on the gel, when compared to a loading
control which shows an array of bands (Fig. 11A; courtesy of Campus Chemical
Instrument Center (CCIC) Mass Spectrometry and Proteomics Facility at The Ohio State
University). Mass spectrometry was not conducted after in-gel digestion, due to the
absence of protein bands to pick for digest.
Subsequently, proteins in the PCCF samples (N=10 per Gleason score group) were
submitted for in-solution digestion. Mass spectrometry output lists were obtained
identifying proteins by abundance, in PCCFs from Gleason score 6 (Appendix C) and 8
(Appendix D) patients. Interestingly, a higher number of proteins were detected in
Gleason 6 samples totaling 203 proteins; while from the Gleason 8 samples a total of 80
proteins were detected. The majority of proteins identified, and those with the largest
number of peptides found in the sample, were serum albumin, immunoglobulins, and
components of the coagulation and complement cascades, as well as cytoskeletonassociated proteins, enzymes, and signaling molecules. The abundance of keratins and
collagens in both groups of PCCF samples could be due to contamination during
handling of the samples.
In the analysis of protein differences between Gleason 6 and 8, one prostate protein was
found in a single Gleason 8 sample from one individual patient, and not found in any of
the Gleason 6 samples. This protein was Prostasin (PRSS8_HUMAN), a
glycosylphosphatidylinositol-anchored serine protease involved in epithelial Na channel
activation (77). However, this protein was only detected in one patient, and in low
abundance.
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Figure 11. SDS-PAGE gel show the difference in protein band identification
between loading controls and a sample consisting of tandem isolated PCCF.
SDS-PAGE gel of controls and tandem isolated PCCF from patient PMP-324. Gel was
stained with coomassie brilliant blue (performed by our Ohio State collaborators), which
reveals clearly visible protein bands in both controls, but no bands in the PMP-324 lane
were detected.
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Chapter 4
Discussion
In this study, we isolated prostate cancer cell fragments (PCCFs) from the plasma of
prostate cancer patients with Gleason scores of 6 and 8, which indicates low and highgrade PCa respectively, in order to assess the protein content of these PCFFs. The goal
was to find a protein specific for each of these PCa grades, which could be used to
discriminate between these two clinically distinct patient cohorts. We created a novel
tandem immunoaffinity isolation technique using two prostate-specific antigens, PSMA
and STEAP1, to separate PCCF from other non-prostate EVs and plasma proteins. The
purity of the samples, assessed by the reduction of background cellular material and
plasma protein, as well as the morphological features of the isolated EVs, were analyzed
with atomic force microscopy and nanoscale flow cytometry.

Extracellular vesicles such as prostate cancer cell fragments
as a fluid biopsy for prostate cancer
Research on EVs began in 1967, when Peter Wolf discovered platelet MPs, but many
regarded EVs as simply ‘cellular debris’. Currently, research in EVs has increased our
understanding of the mechanisms of vesicle production, their role as modulators of
normal physiological processes, as well as in cancer progression and other disease states
(10). It is now known that during microvesicle biogenesis, cell fragments retain
membrane proteins and nucleic acid originally found within the parent cell (78).
Furthermore, studies have confirmed that release of EV is accelerated in cancer (9) and
other diseases (10), feeding interest for their role in mediating cell-to-cell
communication, and as a biomarker platform for improved screening and prognosis of
diseases.

The promise of EVs in PCa may be more suited for biomarker development, considering
that PCCFs are endowed with portions of membrane proteins from the parent cell (78).
Attempts to discover PCCFs-associated biomarkers specific for PCa are limited to
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proteomic analysis of isolated PCCFs from in vitro studies (4), or from human PCa
xenografts in mice (55). However, these reported biomarkers have not been clinically
validated, either in serum or plasma samples, underscoring the need to substantiate
biomarkers beyond the initial discovery phase.

Immunoaffinity isolation of PCCFs
The ability to isolate and enrich EVs, such as exosomes or microparticles, is a highly
important method that is currently not standardized. A significant barrier in discovering
biomarkers associated with EV samples is due to the lack of robust platforms for isolation
of EV populations, with the samples mostly dominated by co-isolated soluble proteins
that may also contain the biomarker of interest (79). As the majority of studies have
failed to evaluate the purity of isolated EV populations before performing downstream
analytical assays, the sample may be a misrepresentation of the EV population of interest,
consequently leading to erroneous conclusions.
A key step in the isolation of EVs from bodily fluids is the reduction of other non-target
factors such as proteins, circulating nucleic acids, and non-target EVs in order to
demonstrate that factors within the target EVs are specific effectors during intercellular
communication (80). The most commonly used method for EV purification is differential
ultracentrifugation (4,31), a practice that many consider the “gold standard” for
purification of EVs (81). However, ultracentrifugation does not guarantee complete
elimination of non-target EVs, resulting in enrichment as opposed to the purification of
the desired EV population (42). Moreover, this technique involves lengthy periods of
centrifugation and requires expensive specialized equipment for ultracentrifugation of the
sample.
As interest in EVs has intensified, so has the demand for procedures which are rapid and
more user-friendly. This has resulted in the creation of several kits which act by
separating exosomes through sedimentation from other factors within the sample; in
particular, ExoQuick (System Bioscience), Total Exosome (Life Technologies) and
ExoSpin (Cell Guidance Systems), which are all commercially available. While these kits
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minimize the time spent performing EV isolation, little is known about their purification
efficacy. Newly published data shows that although the precipitation techniques yield a
higher protein content, this is not an indication of high exosome purification, but rather a
consequence of contaminating non-exosomal proteins (82).
In comparison with the other methods of EV isolation, immunoaffinity-based isolation
methods provide a high level of specificity for selecting EVs from the tissue of interest.
The ability to select a subpopulation of EVs from biological fluids is an essential
requirement for studies focusing on the diagnostic potential of EV (83). In this thesis, we
developed an immunoaffinity isolation protocol using the PSMA antigen, which proved
to be efficient at separating PCCFs from other small vesicles present in plasma samples.
This technique proved to be more effective than all previously mentioned commercially
available kits at removing background subpopulations (Fig. 6A-D). We also created a
tandem isolation method to further eliminate plasma and other contaminating proteins.
Moreover, the use of two prostate antigens (PSMA and STEAP1) was helpful in further
selecting EVs that were prostate specific.

Multi-modal nano-characterization of purified extracellular
vesicles from biological samples
The field of EVs is rapidly evolving in terms of the techniques used for characterizing
vesicles isolated from different sources. In EV characterization, is important to use
several techniques in combination for quantifying and visually analyzing the features of
the vesicles (81). We present here the combined use of nanoscale flow cytometry and
atomic force microscopy as a means to quantify prostate cancer cell fragment events, to
measure them to the atomic level, and visualize their topographical morphology.
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4.3.1 Nanoscale flow cytometry for quantification of PCCFs in plasma
and isolated samples
The emergence of nanoscale flow cytometry (NFC) has made high-throughput, multiparametric analysis of all events between 110 and 880 nm possible regardless of the
incident wavelength of light used (46). Using the Apogee A50-Micro nanoscale flow
cytometer, polystyrene microspheres and silica-based beads can be size-resolved up to
differences of 100 nm (47), revealing the potential of this instrumentation to become
widely used for the analysis of EVs in complex biological mixtures (48).
In the present study, we used the NFC to successfully quantify PCCF events in both
plasma and isolated samples, which expressed the prostate antigens PSMA (Fig. and
STEAP1 (Fig. 8C). The Apogee A50-Micro NFC was also useful in validating the
efficiency of our tandem immunoaffinity method to reduce the population of non-target
EVs and other noise particles from the starting plasma sample (Fig. 9B-D).

4.3.2 Atomic force microscopy for visual characterization and validation
of the isolated PCCFs
Microscopy continues to be a common approach to assessing the efficacy of EV isolation
from a given sample, as well as to characterize the structure and relative size of these
vesicles (42,48). Most publications have reported the use of transmission electron
microscopy (TEM) and scanning electron microscopy (SEM) as key modalities to
visually characterize and evaluate the ratio of EVs to soluble protein and other cellular
debris (42). However, these techniques are not quantitative, as they do not allow for the
atomic measurement of components in the sample, which is important for distinguishing
exosomes (50-100 nm) from microparticles (100-1000 nm).
The atomic force microscope (AFM) has been recently reported to be a valuable tool for
the nanoscale measurement of EVs at atomic resolution (23). This instrument allows for
the topographical imaging of EV surfaces, as well as offering information regarding
protein contamination in purified EVs preparations (84). Moreover, sample preparation
for AFM analysis is rapid and does not alter the native state of the target EV, which is
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substantially different from the lengthy and harsh sample processing required for electron
microscopy (85).
We have shown that AFM is an idea promising imaging modality for the measurement of
small vesicles with a mean diameter of ~100 nm and for the detection of protein
complexes co-isolated with the target population of EVs (Fig. 7A). Images of isolated
PCCFs obtained with AFM also allowed for the 3-dimensional rendering of the particles
(Fig. 7B); depicting the surface of the particles in a 3-dimensional plane led us to
visualize small peaks (Fig. 7C), which we speculate could be protein receptors inherited
from the parental cell.

Mass spectrometry
The great interest in EV as protein carriers is evident in the literature, with a large
number of publications focusing on characterizing the proteome of EVs derived from cell
culture media (14,86) and biological fluids (4,87). Currently, discovery of disease
biomarkers from EVs using mass spectrometry (MS) is mostly from cell culture media
samples. Moreover, the information gained from proteomic analysis of EVs from
biological fluids is limited in the literature. This could be due to the complexity of
proteins that are present in biological fluids. The greatest challenge of performing MS
analysis from blood serum or plasma samples vs. tissue culture is the vast difference in
the dynamic range of proteins. Even with attempts to remove abundant proteins such as
albumin and immunoglobulins, small amounts of impurities can have a significant effect
in MS analysis of isolated EVs, making the identification of low abundance proteins
difficult (87).

In agreement with previous reports, Bastos-Amador et al. (88) showed that plasma
proteins such as albumin, and cytosolic proteins like heat shock proteins were among the
most abundant protein present after EV isolation from plasma samples. They also
reported a high proportion of immunoglobulins co-isolated with their EV preparations.
However, some of these generally co-isolated proteins may be difficult to remove from
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the samples, as they may be purposely packaged in EVs to maintain membrane and
protein integrity (89).

In the present study, the MS results (Appendix A-D) we obtained from isolated PCCFs
are consistent with the literature in regards to the majority of proteins detected by MS
being albumin and immunoglobulins Moreover, the MS output data shows an abundance
of keratins and collagen, which could be due to contamination caused by handling of the
sample during the isolation process, or while preparing the samples for in-solution
digestion. The aim of this part of the study was to find possible protein biomarkers
uniformly expressed in all the PCCF samples from one Gleason score group that were not
expressed in the other Gleason score group. Although there were some proteins which
were differentially expressed between these two Gleason scores, these were found in only
one or two of the samples, but not the rest. In addition, only a small number of peptides
from some of these proteins were identified. Like our results, another group has similarly
reported that they were able to identify a small number of proteins in EVs isolated from
plasma (90).

The inability to detect the expected quantity of proteins in our PCCF samples could be
due to intrinsic issues with the tandem immunoaffinity method we developed. This
technique requires the use of elution buffers that modify the pH of the sample. Although
physiological pH was restored immediately, exposing the PCCFs to the conditions of the
eluting buffer could have affected the three-dimensional structure of proteins assembled
on the PCCF surface (91). Consequently, alteration of the biological properties of
proteins in the isolated PCCF could have resulted in inability to detect these proteins with
MS.

Significance
Currently, there is a need for new diagnostic tools to accurately identify patients with
aggressive or high-risk PCa from those with low-risk disease. Prostate specific antigen
(PSA) testing continues to be employed as a monitoring and prognostication tool;
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however, PSA is produced and secreted by both normal prostate epithelium and PCa into
the circulation (4). The low specificity and high false-positive rate of PSA have resulted
in many men without PCa having to undergo painful and unnecessary biopsies and risk
the possibility of infections post-biopsy. As a result, PSA is no longer recommended as
the leading test for PCa screening (73).

Research to discover new diagnostic biomarkers that could differentiate low-risk from
high-risk PCa has not significantly progressed, but the need for a non-invasive test in
monitoring PCa patients is clearly of great clinical value. PCCFs are an attractive
biomarker platform for detecting PCa, as these fragments originate from prostate
epithelium or from malignant cells within the primary tumor and are released into the
blood circulation (76). Moreover, it has been previously shown that significant quantities
of PCCFs are detectable in samples from PCa patients, but are not detected in healthy
individuals (92).

In general, the PCa research community must double its efforts to understand
extracellular vesicles like PCCFs in order to apply these fragments as a novel noninvasive biomarker-based test. Biomarkers that arise out of these studies could eventually
become clinically validated. Upon development of biomarkers specific to PCCFs from
Gleason score 6 and 8 lesions, a "liquid biopsy" format of the Gleason score could be
established to evaluate patients prior to biopsy, and determine the stage of cancer. This is
a major clinically unmet need, which may aid clinicians towards a more precise means of
managing PCa. Such a test would also provide major health costs savings, as well as
minimize patient morbidity and anxiety related to the biopsy procedure.

Future directions and conclusions
Future studies will need to focus on further optimizing the tandem isolation protocol to
allow for the maximum collection of PCCFs to produce a higher yield of prostate-specific
proteins. This may be partially overcome by scaling up the isolation with a higher volume
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of initial plasma. Previously, an initial volume of <1 mL has been used for the isolation
of EV from complex biological fluids (81), which is a feasible volume of starting sample
to collect from patients.

To further support future efforts in finding independent biomarkers for each Gleason
score (GS 6 and 8), the small sample size in this study (N=10 per Gleason score cohort)
should be significantly increased. A larger sample size could guarantee a better
representation of the population, as well as detection of low-abundance proteins in
additional samples.

In addition, using antibodies with higher affinity for the target populations could
potentially have utility, as we only tested one antibody for each target antigen (PSMA
and STEAP1). Using a cocktail of l antibodies could be better if the target epitope is not
always available.

Although we proved with NFC and AFM that there is a significant reduction of the noise
population when using our tandem isolation method, we still detected co-isolated plasma
and cytosolic proteins. These co-isolated proteins could be masking the expression of
other, less abundant proteins. Therefore, it is important to effectively separate the target
EV, in order to avoid the background caused by these co-isolated protein aggregates (91).
The use of albumin/IgG removal kits has been previously proposed in order to achieve
the depletion of plasma and cytosolic proteins (81). This step could be introduced prior to
the tandem immunoaffinity isolation technique.
To our knowledge, this is the first evidence that the tandem affinity methodology is
effective at reducing other non-target EVs and proteins from PCa patient samples while
keeping a significant number of PCCFs. We showed that using our tandem affinity
technique is more efficient than other isolation methods - such as commercial EV
purification kits - in removing soluble proteins and other debris from the sample.
Moreover, we also showed that the combined use of nanoscale flow cytometry and
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atomic force microscopy has a great potential to become a widely used technique to
analyze extracellular vesicle enrichment.
In the current study, we were not able to identify protein biomarkers for differentiating
the two patient cohorts (Gleason score 6 and 8), which was the principal goal of this
thesis. However, future efforts in optimizing the protocols we have developed in this
project could help in the identification of protein biomarkers for better and faster
diagnosis and staging of prostate cancer.
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Appendices
Appendix A: List of proteins identified in PCCF isolated using biotinylated PSMA
immunoaffinity method from plasma of patients with Gleason score 6.
Accession

Description

ALBU_HUMAN

Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2

CO3_HUMAN

Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2

CFAH_HUMAN

Complement factor H OS=Homo sapiens GN=CFH PE=1 SV=4

A2MG_HUMAN

Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1
SV=3

APOB_HUMAN

Apolipoprotein B-100 OS=Homo sapiens GN=APOB PE=1
SV=2

CO4A_HUMAN

Complement C4-A OS=Homo sapiens GN=C4A PE=1 SV=2

CO4B_HUMAN

Complement C4-B OS=Homo sapiens GN=C4B PE=1 SV=2

TRFE_HUMAN

Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3

FINC_HUMAN

Fibronectin OS=Homo sapiens GN=FN1 PE=1 SV=4

HPT_HUMAN

Haptoglobin OS=Homo sapiens GN=HP PE=1 SV=1

CFAB_HUMAN

Complement factor B OS=Homo sapiens GN=CFB PE=1 SV=2

PLMN_HUMAN

Plasminogen OS=Homo sapiens GN=PLG PE=1 SV=2

K2C1_HUMAN

Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1
PE=1 SV=6

VTDB_HUMAN

Vitamin D-binding protein OS=Homo sapiens GN=GC PE=1
SV=1
Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10
PE=1 SV=6

K1C10_HUMAN
IGHG3_HUMAN
IGHM_HUMAN

Ig gamma-3 chain C region OS=Homo sapiens GN=IGHG3
PE=1 SV=2
Ig mu chain C region OS=Homo sapiens GN=IGHM PE=1 SV=3
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ITIH4_HUMAN

Inter-alpha-trypsin inhibitor heavy chain H4 OS=Homo sapiens
GN=ITIH4 PE=1 SV=4

A1BG_HUMAN

Alpha-1B-glycoprotein OS=Homo sapiens GN=A1BG PE=1
SV=4

FETUA_HUMAN

Alpha-2-HS-glycoprotein OS=Homo sapiens GN=AHSG PE=1
SV=1

K22E_HUMAN

Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens
GN=KRT2 PE=1 SV=2

HPTR_HUMAN

Haptoglobin-related protein OS=Homo sapiens GN=HPR PE=2
SV=2

C4BPA_HUMAN

C4b-binding protein alpha chain OS=Homo sapiens GN=C4BPA
PE=1 SV=2

K1C9_HUMAN

Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9
PE=1 SV=3

CERU_HUMAN

Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1

IGHG4_HUMAN

Ig gamma-4 chain C region OS=Homo sapiens GN=IGHG4
PE=1 SV=1

KNG1_HUMAN

Kininogen-1 OS=Homo sapiens GN=KNG1 PE=1 SV=2

THRB_HUMAN

Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2

IGHG1_HUMAN

Ig gamma-1 chain C region OS=Homo sapiens GN=IGHG1
PE=1 SV=1
Alpha-1-acid glycoprotein 1 OS=Homo sapiens GN=ORM1
PE=1 SV=1

A1AG1_HUMAN
CO5_HUMAN

Complement C5 OS=Homo sapiens GN=C5 PE=1 SV=4

IGKC_HUMAN

Ig kappa chain C region OS=Homo sapiens GN=IGKC PE=1
SV=1
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IGHG2_HUMAN

Ig gamma-2 chain C region OS=Homo sapiens GN=IGHG2
PE=1 SV=2

CO8B_HUMAN

Complement component C8 beta chain OS=Homo sapiens
GN=C8B PE=1 SV=3

AFAM_HUMAN

Afamin OS=Homo sapiens GN=AFM PE=1 SV=1

AMBP_HUMAN

Protein AMBP OS=Homo sapiens GN=AMBP PE=1 SV=1

CO7_HUMAN

Complement component C7 OS=Homo sapiens GN=C7 PE=1
SV=2

VWF_HUMAN

von Willebrand factor OS=Homo sapiens GN=VWF PE=1 SV=4

MUCB_HUMAN

Ig mu heavy chain disease protein OS=Homo sapiens PE=1
SV=1

IGJ_HUMAN

Immunoglobulin J chain OS=Homo sapiens GN=JCHAIN PE=1
SV=4

APOH_HUMAN

Beta-2-glycoprotein 1 OS=Homo sapiens GN=APOH PE=1
SV=3

A1AG2_HUMAN

Alpha-1-acid glycoprotein 2 OS=Homo sapiens GN=ORM2
PE=1 SV=2

IGHA1_HUMAN

Ig alpha-1 chain C region OS=Homo sapiens GN=IGHA1 PE=1
SV=2

CO6_HUMAN

Complement component C6 OS=Homo sapiens GN=C6 PE=1
SV=3
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APOA1_HUMAN

Apolipoprotein A-I OS=Homo sapiens GN=APOA1 PE=1 SV=1

C1S_HUMAN

Complement C1s subcomponent OS=Homo sapiens GN=C1S
PE=1 SV=1

C1R_HUMAN

Complement C1r subcomponent OS=Homo sapiens GN=C1R
PE=1 SV=2

CD5L_HUMAN

CD5 antigen-like OS=Homo sapiens GN=CD5L PE=1 SV=1

CO9_HUMAN

Complement component C9 OS=Homo sapiens GN=C9 PE=1
SV=2

LAC2_HUMAN

Ig lambda-2 chain C regions OS=Homo sapiens GN=IGLC2
PE=1 SV=1

A1AT_HUMAN

Alpha-1-antitrypsin OS=Homo sapiens GN=SERPINA1 PE=1
SV=3

GELS_HUMAN

Gelsolin OS=Homo sapiens GN=GSN PE=1 SV=1

K2C6B_HUMAN

Keratin, type II cytoskeletal 6B OS=Homo sapiens GN=KRT6B
PE=1 SV=5

CFAI_HUMAN

Complement factor I OS=Homo sapiens GN=CFI PE=1 SV=2

ITIH1_HUMAN

Inter-alpha-trypsin inhibitor heavy chain H1 OS=Homo sapiens
GN=ITIH1 PE=1 SV=3

AACT_HUMAN

Alpha-1-antichymotrypsin OS=Homo sapiens GN=SERPINA3
PE=1 SV=2
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LAC3_HUMAN

Ig lambda-3 chain C regions OS=Homo sapiens GN=IGLC3
PE=1 SV=1

CO2_HUMAN

Complement C2 OS=Homo sapiens GN=C2 PE=1 SV=2

ITIH2_HUMAN

Inter-alpha-trypsin inhibitor heavy chain H2 OS=Homo sapiens
GN=ITIH2 PE=1 SV=2
Complement component C8 alpha chain OS=Homo sapiens
GN=C8A PE=1 SV=2

CO8A_HUMAN
PROS_HUMAN
K1C14_HUMAN

Vitamin K-dependent protein S OS=Homo sapiens GN=PROS1
PE=1 SV=1
Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14
PE=1 SV=4

ACTB_HUMAN

Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1

CLUS_HUMAN

Clusterin OS=Homo sapiens GN=CLU PE=1 SV=1

PON1_HUMAN

Serum paraoxonase/arylesterase 1 OS=Homo sapiens GN=PON1
PE=1 SV=3

HEP2_HUMAN

Heparin cofactor 2 OS=Homo sapiens GN=SERPIND1 PE=1
SV=3

PZP_HUMAN

Pregnancy zone protein OS=Homo sapiens GN=PZP PE=1 SV=4

K2C5_HUMAN

Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5
PE=1 SV=3

VTNC_HUMAN

Vitronectin OS=Homo sapiens GN=VTN PE=1 SV=1
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IGLL5_HUMAN

Immunoglobulin lambda-like polypeptide 5 OS=Homo sapiens
GN=IGLL5 PE=2 SV=2

IGHA2_HUMAN

Ig alpha-2 chain C region OS=Homo sapiens GN=IGHA2 PE=1
SV=3

ANT3_HUMAN

Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1
SV=1

HEMO_HUMAN

Hemopexin OS=Homo sapiens GN=HPX PE=1 SV=2

APOE_HUMAN

Apolipoprotein E OS=Homo sapiens GN=APOE PE=1 SV=1

KLKB1_HUMAN

Plasma kallikrein OS=Homo sapiens GN=KLKB1 PE=1 SV=1

A2GL_HUMAN

Leucine-rich alpha-2-glycoprotein OS=Homo sapiens GN=LRG1
PE=1 SV=2

FHR1_HUMAN

Complement factor H-related protein 1 OS=Homo sapiens
GN=CFHR1 PE=1 SV=2

POTEF_HUMAN

POTE ankyrin domain family member F OS=Homo sapiens
GN=POTEF PE=1 SV=2

ANXA2_HUMAN

Annexin A2 OS=Homo sapiens GN=ANXA2 PE=1 SV=2

KV305_HUMAN

Ig kappa chain V-III region WOL OS=Homo sapiens PE=1
SV=1
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1433S_HUMAN

14-3-3 protein sigma OS=Homo sapiens GN=SFN PE=1 SV=1

C1QC_HUMAN

Complement C1q subcomponent subunit C OS=Homo sapiens
GN=C1QC PE=1 SV=3

APOA4_HUMAN

Apolipoprotein A-IV OS=Homo sapiens GN=APOA4 PE=1
SV=3

FHR4_HUMAN

Complement factor H-related protein 4 OS=Homo sapiens
GN=CFHR4 PE=1 SV=3

FIBA_HUMAN

Fibrinogen alpha chain OS=Homo sapiens GN=FGA PE=1
SV=2

FBLN1_HUMAN

Fibulin-1 OS=Homo sapiens GN=FBLN1 PE=1 SV=4

APOL1_HUMAN

Apolipoprotein L1 OS=Homo sapiens GN=APOL1 PE=1 SV=5

TTHY_HUMAN

Transthyretin OS=Homo sapiens GN=TTR PE=1 SV=1

HBB_HUMAN

Hemoglobin subunit beta OS=Homo sapiens GN=HBB PE=1
SV=2

KPYM_HUMAN

Pyruvate kinase PKM OS=Homo sapiens GN=PKM PE=1 SV=4

ITIH3_HUMAN

Inter-alpha-trypsin inhibitor heavy chain H3 OS=Homo sapiens
GN=ITIH3 PE=1 SV=2

HABP2_HUMAN

Hyaluronan-binding protein 2 OS=Homo sapiens GN=HABP2
PE=1 SV=1

85

PEDF_HUMAN

Pigment epithelium-derived factor OS=Homo sapiens
GN=SERPINF1 PE=1 SV=4

KR510_HUMAN

Keratin-associated protein 5-10 OS=Homo sapiens
GN=KRTAP5-10 PE=2 SV=1

KRA54_HUMAN

Keratin-associated protein 5-4 OS=Homo sapiens GN=KRTAP54 PE=2 SV=1

KRA53_HUMAN

Keratin-associated protein 5-3 OS=Homo sapiens GN=KRTAP53 PE=2 SV=1

FHR2_HUMAN

Complement factor H-related protein 2 OS=Homo sapiens
GN=CFHR2 PE=1 SV=1

K1C16_HUMAN

Keratin, type I cytoskeletal 16 OS=Homo sapiens GN=KRT16
PE=1 SV=4

LDHA_HUMAN

L-lactate dehydrogenase A chain OS=Homo sapiens GN=LDHA
PE=1 SV=2

LV302_HUMAN

Ig lambda chain V-III region LOI OS=Homo sapiens PE=1
SV=1
Ig kappa chain V-III region B6 OS=Homo sapiens PE=1 SV=1

KV301_HUMAN
HRG_HUMAN
CO8G_HUMAN

Histidine-rich glycoprotein OS=Homo sapiens GN=HRG PE=1
SV=1
Complement component C8 gamma chain OS=Homo sapiens
GN=C8G PE=1 SV=3

SAMP_HUMAN

Serum amyloid P-component OS=Homo sapiens GN=APCS
PE=1 SV=2

KV204_HUMAN

Ig kappa chain V-II region TEW OS=Homo sapiens PE=1 SV=1

KV203_HUMAN

Ig kappa chain V-II region MIL OS=Homo sapiens PE=1 SV=1

ATRN_HUMAN

Attractin OS=Homo sapiens GN=ATRN PE=1 SV=2

DCD_HUMAN

Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2
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G3P_HUMAN

Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens
GN=GAPDH PE=1 SV=3

FCN3_HUMAN

Ficolin-3 OS=Homo sapiens GN=FCN3 PE=1 SV=2

APOA_HUMAN

Apolipoprotein(a) OS=Homo sapiens GN=LPA PE=1 SV=1

ALDOA_HUMAN Fructose-bisphosphate aldolase A OS=Homo sapiens
GN=ALDOA PE=1 SV=2
FA12_HUMAN

Coagulation factor XII OS=Homo sapiens GN=F12 PE=1 SV=3

C1QB_HUMAN

Complement C1q subcomponent subunit B OS=Homo sapiens
GN=C1QB PE=1 SV=3

TBA1A_HUMAN

Tubulin alpha-1A chain OS=Homo sapiens GN=TUBA1A PE=1
SV=1

TETN_HUMAN

Tetranectin OS=Homo sapiens GN=CLEC3B PE=1 SV=3

LRP1_HUMAN

Prolow-density lipoprotein receptor-related protein 1 OS=Homo
sapiens GN=LRP1 PE=1 SV=2

KRA44_HUMAN

Keratin-associated protein 4-4 OS=Homo sapiens GN=KRTAP44 PE=2 SV=1

HV301_HUMAN

Ig heavy chain V-III region TRO OS=Homo sapiens PE=1 SV=1

MYH9_HUMAN

Myosin-9 OS=Homo sapiens GN=MYH9 PE=1 SV=4

VIME_HUMAN

Vimentin OS=Homo sapiens GN=VIM PE=1 SV=4

MBL2_HUMAN

Mannose-binding protein C OS=Homo sapiens GN=MBL2 PE=1
SV=2

HSPB1_HUMAN

Heat shock protein beta-1 OS=Homo sapiens GN=HSPB1 PE=1
SV=2
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CBPB2_HUMAN

Carboxypeptidase B2 OS=Homo sapiens GN=CPB2 PE=1 SV=2

SEPP1_HUMAN

Selenoprotein P OS=Homo sapiens GN=SEPP1 PE=1 SV=3

HBA_HUMAN

Hemoglobin subunit alpha OS=Homo sapiens GN=HBA1 PE=1
SV=2

LG3BP_HUMAN

Galectin-3-binding protein OS=Homo sapiens GN=LGALS3BP
PE=1 SV=1

APOD_HUMAN

Apolipoprotein D OS=Homo sapiens GN=APOD PE=1 SV=1

FETUB_HUMAN

Fetuin-B OS=Homo sapiens GN=FETUB PE=1 SV=2

ANXA1_HUMAN

Annexin A1 OS=Homo sapiens GN=ANXA1 PE=1 SV=2

A2AP_HUMAN

Alpha-2-antiplasmin OS=Homo sapiens GN=SERPINF2 PE=1
SV=3

APOM_HUMAN

Apolipoprotein M OS=Homo sapiens GN=APOM PE=1 SV=2

HV101_HUMAN

Ig heavy chain V-I region EU OS=Homo sapiens PE=1 SV=1

TSP1_HUMAN

Thrombospondin-1 OS=Homo sapiens GN=THBS1 PE=1 SV=2

KV101_HUMAN

Ig kappa chain V-I region AG OS=Homo sapiens PE=1 SV=1

KV111_HUMAN

Ig kappa chain V-I region Ka OS=Homo sapiens PE=1 SV=1
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GSTP1_HUMAN

Glutathione S-transferase P OS=Homo sapiens GN=GSTP1
PE=1 SV=2

KV310_HUMAN

Ig kappa chain V-III region VH (Fragment) OS=Homo sapiens
PE=4 SV=1

KV306_HUMAN

Ig kappa chain V-III region POM OS=Homo sapiens PE=1 SV=1

KV308_HUMAN

Ig kappa chain V-III region CLL OS=Homo sapiens PE=4 SV=2

ECM1_HUMAN

Extracellular matrix protein 1 OS=Homo sapiens GN=ECM1
PE=1 SV=2

DESP_HUMAN

Desmoplakin OS=Homo sapiens GN=DSP PE=1 SV=3

CALM_HUMAN

Calmodulin OS=Homo sapiens GN=CALM1 PE=1 SV=2

SAA1_HUMAN

Serum amyloid A-1 protein OS=Homo sapiens GN=SAA1 PE=1
SV=1

FA10_HUMAN

Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2

SHBG_HUMAN

Sex hormone-binding globulin OS=Homo sapiens GN=SHBG
PE=1 SV=2

EF1A1_HUMAN

Elongation factor 1-alpha 1 OS=Homo sapiens GN=EEF1A1
PE=1 SV=1

LCE2B_HUMAN

Late cornified envelope protein 2B OS=Homo sapiens
GN=LCE2B PE=2 SV=1

KRA59_HUMAN

Keratin-associated protein 5-9 OS=Homo sapiens GN=KRTAP59 PE=1 SV=1
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LAMC1_HUMAN

Laminin subunit gamma-1 OS=Homo sapiens GN=LAMC1
PE=1 SV=3

MT2_HUMAN

Metallothionein-2 OS=Homo sapiens GN=MT2A PE=1 SV=1

KRA51_HUMAN

Keratin-associated protein 5-1 OS=Homo sapiens GN=KRTAP51 PE=2 SV=1

FA9_HUMAN

Coagulation factor IX OS=Homo sapiens GN=F9 PE=1 SV=2

TENX_HUMAN

Tenascin-X OS=Homo sapiens GN=TNXB PE=1 SV=4

MT1L_HUMAN

Metallothionein-1L OS=Homo sapiens GN=MT1L PE=2 SV=1

STAB1_HUMAN

Stabilin-1 OS=Homo sapiens GN=STAB1 PE=1 SV=3

KRA57_HUMAN

Keratin-associated protein 5-7 OS=Homo sapiens GN=KRTAP57 PE=2 SV=1

MT1DP_HUMAN

Putative metallothionein MT1DP OS=Homo sapiens
GN=MT1DP PE=5 SV=1
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Appendix B: List of proteins identified in PCCF isolated using tandem
immunoaffinity method from plasma of patients with Gleason score 8.
Accession
APOB_HUMAN

Description
Apolipoprotein B-100 OS=Homo sapiens GN=APOB PE=1
SV=2

CO3_HUMAN

Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2

MYH9_HUMAN

Myosin-9 OS=Homo sapiens GN=MYH9 PE=1 SV=4

FLNA_HUMAN

Filamin-A OS=Homo sapiens GN=FLNA PE=1 SV=4

TLN1_HUMAN
CO4A_HUMAN

Talin-1 OS=Homo sapiens GN=TLN1 PE=1 SV=3
Complement C4-A OS=Homo sapiens GN=C4A PE=1 SV=2

CO4B_HUMAN

Complement C4-B OS=Homo sapiens GN=C4B PE=1 SV=2

A2MG_HUMAN

Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1
SV=3

ALBU_HUMAN

Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2

A1AT_HUMAN

Alpha-1-antitrypsin OS=Homo sapiens GN=SERPINA1 PE=1
SV=3

FIBB_HUMAN

Fibrinogen beta chain OS=Homo sapiens GN=FGB PE=1 SV=2

FIBA_HUMAN

Fibrinogen alpha chain OS=Homo sapiens GN=FGA PE=1
SV=2

CERU_HUMAN

Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1

APOA1_HUMAN

Apolipoprotein A-I OS=Homo sapiens GN=APOA1 PE=1 SV=1

ITIH4_HUMAN

Inter-alpha-trypsin inhibitor heavy chain H4 OS=Homo sapiens
GN=ITIH4 PE=1 SV=4

ITIH2_HUMAN

Inter-alpha-trypsin inhibitor heavy chain H2 OS=Homo sapiens
GN=ITIH2 PE=1 SV=2

TSP1_HUMAN

Thrombospondin-1 OS=Homo sapiens GN=THBS1 PE=1 SV=2

GELS_HUMAN
TRFE_HUMAN

Gelsolin OS=Homo sapiens GN=GSN PE=1 SV=1
Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3

ITA2B_HUMAN

Integrin alpha-IIb OS=Homo sapiens GN=ITGA2B PE=1 SV=3
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CFAB_HUMAN

Complement factor B OS=Homo sapiens GN=CFB PE=1 SV=2

ACTB_HUMAN

Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1

AACT_HUMAN

Alpha-1-antichymotrypsin OS=Homo sapiens GN=SERPINA3
PE=1 SV=2

K2C1_HUMAN

Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1
PE=1 SV=6

FIBG_HUMAN

Fibrinogen gamma chain OS=Homo sapiens GN=FGG PE=1
SV=3

K22E_HUMAN

Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens
GN=KRT2 PE=1 SV=2

FA5_HUMAN

Coagulation factor V OS=Homo sapiens GN=F5 PE=1 SV=4

HPT_HUMAN
ITIH1_HUMAN

Haptoglobin OS=Homo sapiens GN=HP PE=1 SV=1
Inter-alpha-trypsin inhibitor heavy chain H1 OS=Homo sapiens
GN=ITIH1 PE=1 SV=3

ANT3_HUMAN

Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1
SV=1

CFAH_HUMAN

Complement factor H OS=Homo sapiens GN=CFH PE=1 SV=4

CO5_HUMAN

Complement C5 OS=Homo sapiens GN=C5 PE=1 SV=4

K1C10_HUMAN

Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10
PE=1 SV=6

FINC_HUMAN
APOA4_HUMAN

Fibronectin OS=Homo sapiens GN=FN1 PE=1 SV=4
Apolipoprotein A-IV OS=Homo sapiens GN=APOA4 PE=1
SV=3

MMRN1_HUMAN Multimerin-1 OS=Homo sapiens GN=MMRN1 PE=1 SV=3
TPM4_HUMAN

Tropomyosin alpha-4 chain OS=Homo sapiens GN=TPM4 PE=1
SV=3

ACTN1_HUMAN

Alpha-actinin-1 OS=Homo sapiens GN=ACTN1 PE=1 SV=2

HPTR_HUMAN

Haptoglobin-related protein OS=Homo sapiens GN=HPR PE=2
SV=2

A1BG_HUMAN

Alpha-1B-glycoprotein OS=Homo sapiens GN=A1BG PE=1
SV=4

TBB1_HUMAN

Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1
SV=1

VINC_HUMAN

Vinculin OS=Homo sapiens GN=VCL PE=1 SV=4
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ACTC_HUMAN

Actin, alpha cardiac muscle 1 OS=Homo sapiens GN=ACTC1
PE=1 SV=1

IGHG1_HUMAN

Ig gamma-1 chain C region OS=Homo sapiens GN=IGHG1
PE=1 SV=1

CO9_HUMAN

Complement component C9 OS=Homo sapiens GN=C9 PE=1
SV=2

APOE_HUMAN

Apolipoprotein E OS=Homo sapiens GN=APOE PE=1 SV=1

K1C9_HUMAN

Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9
PE=1 SV=3

CO6_HUMAN

Complement component C6 OS=Homo sapiens GN=C6 PE=1
SV=3

IGHA1_HUMAN

Ig alpha-1 chain C region OS=Homo sapiens GN=IGHA1 PE=1
SV=2

IGHM_HUMAN

Ig mu chain C region OS=Homo sapiens GN=IGHM PE=1
SV=3

ANGT_HUMAN

Angiotensinogen OS=Homo sapiens GN=AGT PE=1 SV=1

IGHG3_HUMAN

Ig gamma-3 chain C region OS=Homo sapiens GN=IGHG3
PE=1 SV=2

HEMO_HUMAN

Hemopexin OS=Homo sapiens GN=HPX PE=1 SV=2

IGHA2_HUMAN

Ig alpha-2 chain C region OS=Homo sapiens GN=IGHA2 PE=1
SV=3

TTHY_HUMAN

Transthyretin OS=Homo sapiens GN=TTR PE=1 SV=1

HEP2_HUMAN

Heparin cofactor 2 OS=Homo sapiens GN=SERPIND1 PE=1
SV=3

CBG_HUMAN

Corticosteroid-binding globulin OS=Homo sapiens
GN=SERPINA6 PE=1 SV=1

TBA4A_HUMAN

Tubulin alpha-4A chain OS=Homo sapiens GN=TUBA4A PE=1
SV=1

IC1_HUMAN

Plasma protease C1 inhibitor OS=Homo sapiens
GN=SERPING1 PE=1 SV=2

HBB_HUMAN

Hemoglobin subunit beta OS=Homo sapiens GN=HBB PE=1
SV=2

CLUS_HUMAN
HRG_HUMAN

Clusterin OS=Homo sapiens GN=CLU PE=1 SV=1
Histidine-rich glycoprotein OS=Homo sapiens GN=HRG PE=1
SV=1

VTDB_HUMAN

Vitamin D-binding protein OS=Homo sapiens GN=GC PE=1
SV=1
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THBG_HUMAN

Thyroxine-binding globulin OS=Homo sapiens GN=SERPINA7
PE=1 SV=2

C1S_HUMAN

Complement C1s subcomponent OS=Homo sapiens GN=C1S
PE=1 SV=1

CO8B_HUMAN

Complement component C8 beta chain OS=Homo sapiens
GN=C8B PE=1 SV=3

STOM_HUMAN

Erythrocyte band 7 integral membrane protein OS=Homo
sapiens GN=STOM PE=1 SV=3

ATPB_HUMAN

ATP synthase subunit beta, mitochondrial OS=Homo sapiens
GN=ATP5B PE=1 SV=3

GRP78_HUMAN

78 kDa glucose-regulated protein OS=Homo sapiens
GN=HSPA5 PE=1 SV=2

IGHG4_HUMAN

Ig gamma-4 chain C region OS=Homo sapiens GN=IGHG4
PE=1 SV=1

IGHG2_HUMAN

Ig gamma-2 chain C region OS=Homo sapiens GN=IGHG2
PE=1 SV=2

K2C5_HUMAN

Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5
PE=1 SV=3

SAMP_HUMAN

Serum amyloid P-component OS=Homo sapiens GN=APCS
PE=1 SV=2

1433Z_HUMAN

14-3-3 protein zeta/delta OS=Homo sapiens GN=YWHAZ PE=1
SV=1

APOA2_HUMAN

Apolipoprotein A-II OS=Homo sapiens GN=APOA2 PE=1
SV=1

ITB3_HUMAN

Integrin beta-3 OS=Homo sapiens GN=ITGB3 PE=1 SV=2

TBA1A_HUMAN

Tubulin alpha-1A chain OS=Homo sapiens GN=TUBA1A PE=1
SV=1

KNG1_HUMAN

Kininogen-1 OS=Homo sapiens GN=KNG1 PE=1 SV=2

PLMN_HUMAN

Plasminogen OS=Homo sapiens GN=PLG PE=1 SV=2

GP1BA_HUMAN

Platelet glycoprotein Ib alpha chain OS=Homo sapiens
GN=GP1BA PE=1 SV=2

APOL1_HUMAN

Apolipoprotein L1 OS=Homo sapiens GN=APOL1 PE=1 SV=5

PROS_HUMAN

Vitamin K-dependent protein S OS=Homo sapiens GN=PROS1
PE=1 SV=1

A2AP_HUMAN

Alpha-2-antiplasmin OS=Homo sapiens GN=SERPINF2 PE=1
SV=3

IGLL5_HUMAN

Immunoglobulin lambda-like polypeptide 5 OS=Homo sapiens
GN=IGLL5 PE=2 SV=2
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LAC7_HUMAN

Ig lambda-7 chain C region OS=Homo sapiens GN=IGLC7
PE=4 SV=2

VTNC_HUMAN
MYL6_HUMAN

Vitronectin OS=Homo sapiens GN=VTN PE=1 SV=1
Myosin light polypeptide 6 OS=Homo sapiens GN=MYL6 PE=1
SV=2

ML12A_HUMAN

Myosin regulatory light chain 12A OS=Homo sapiens
GN=MYL12A PE=1 SV=2

RET4_HUMAN

Retinol-binding protein 4 OS=Homo sapiens GN=RBP4 PE=1
SV=3

SDPR_HUMAN

Serum deprivation-response protein OS=Homo sapiens
GN=SDPR PE=1 SV=3

CO7_HUMAN

Complement component C7 OS=Homo sapiens GN=C7 PE=1
SV=2

AT2A3_HUMAN

Sarcoplasmic/endoplasmic reticulum calcium ATPase 3
OS=Homo sapiens GN=ATP2A3 PE=1 SV=2

IDHP_HUMAN

Isocitrate dehydrogenase [NADP], mitochondrial OS=Homo
sapiens GN=IDH2 PE=1 SV=2

A2GL_HUMAN

Leucine-rich alpha-2-glycoprotein OS=Homo sapiens
GN=LRG1 PE=1 SV=2

C1R_HUMAN

Complement C1r subcomponent OS=Homo sapiens GN=C1R
PE=1 SV=2

F13A_HUMAN

Coagulation factor XIII A chain OS=Homo sapiens GN=F13A1
PE=1 SV=4

IGKC_HUMAN

Ig kappa chain C region OS=Homo sapiens GN=IGKC PE=1
SV=1

TBB5_HUMAN

Tubulin beta chain OS=Homo sapiens GN=TUBB PE=1 SV=2

LAC2_HUMAN

Ig lambda-2 chain C regions OS=Homo sapiens GN=IGLC2
PE=1 SV=1

PON1_HUMAN

Serum paraoxonase/arylesterase 1 OS=Homo sapiens
GN=PON1 PE=1 SV=3

HBA_HUMAN

Hemoglobin subunit alpha OS=Homo sapiens GN=HBA1 PE=1
SV=2

TBA8_HUMAN

Tubulin alpha-8 chain OS=Homo sapiens GN=TUBA8 PE=1
SV=1

MYL9_HUMAN

Myosin regulatory light polypeptide 9 OS=Homo sapiens
GN=MYL9 PE=1 SV=4

THRB_HUMAN
RAB1B_HUMAN

Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2
Ras-related protein Rab-1B OS=Homo sapiens GN=RAB1B
PE=1 SV=1

RAB1A_HUMAN

Ras-related protein Rab-1A OS=Homo sapiens GN=RAB1A
PE=1 SV=3
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PEDF_HUMAN

Pigment epithelium-derived factor OS=Homo sapiens
GN=SERPINF1 PE=1 SV=4

G3P_HUMAN

Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens
GN=GAPDH PE=1 SV=3

LTBP1_HUMAN

Latent-transforming growth factor beta-binding protein 1
OS=Homo sapiens GN=LTBP1 PE=1 SV=4

CALX_HUMAN
VDAC3_HUMAN

Calnexin OS=Homo sapiens GN=CANX PE=1 SV=2
Voltage-dependent anion-selective channel protein 3 OS=Homo
sapiens GN=VDAC3 PE=1 SV=1

KPYM_HUMAN

Pyruvate kinase PKM OS=Homo sapiens GN=PKM PE=1 SV=4

ALDOA_HUMAN

Fructose-bisphosphate aldolase A OS=Homo sapiens
GN=ALDOA PE=1 SV=2

HSP72_HUMAN

Heat shock-related 70 kDa protein 2 OS=Homo sapiens
GN=HSPA2 PE=1 SV=1

C4BPA_HUMAN

C4b-binding protein alpha chain OS=Homo sapiens GN=C4BPA
PE=1 SV=2

CALD1_HUMAN

Caldesmon OS=Homo sapiens GN=CALD1 PE=1 SV=3

CO8A_HUMAN

Complement component C8 alpha chain OS=Homo sapiens
GN=C8A PE=1 SV=2

AFAM_HUMAN
LUM_HUMAN
ITIH3_HUMAN

Afamin OS=Homo sapiens GN=AFM PE=1 SV=1
Lumican OS=Homo sapiens GN=LUM PE=1 SV=2
Inter-alpha-trypsin inhibitor heavy chain H3 OS=Homo sapiens
GN=ITIH3 PE=1 SV=2

1B07_HUMAN

HLA class I histocompatibility antigen, B-7 alpha chain
OS=Homo sapiens GN=HLA-B PE=1 SV=3

1A68_HUMAN

HLA class I histocompatibility antigen, A-68 alpha chain
OS=Homo sapiens GN=HLA-A PE=1 SV=4

PHLD_HUMAN

Phosphatidylinositol-glycan-specific phospholipase D
OS=Homo sapiens GN=GPLD1 PE=1 SV=3

K1C13_HUMAN

Keratin, type I cytoskeletal 13 OS=Homo sapiens GN=KRT13
PE=1 SV=4

KV312_HUMAN

Ig kappa chain V-III region HAH OS=Homo sapiens PE=2
SV=1

FETUA_HUMAN

Alpha-2-HS-glycoprotein OS=Homo sapiens GN=AHSG PE=1
SV=1

1433G_HUMAN

14-3-3 protein gamma OS=Homo sapiens GN=YWHAG PE=1
SV=2

1433E_HUMAN

14-3-3 protein epsilon OS=Homo sapiens GN=YWHAE PE=1
SV=1
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1433F_HUMAN

14-3-3 protein eta OS=Homo sapiens GN=YWHAH PE=1 SV=4

C1QB_HUMAN

Complement C1q subcomponent subunit B OS=Homo sapiens
GN=C1QB PE=1 SV=3

CXCL7_HUMAN

Platelet basic protein OS=Homo sapiens GN=PPBP PE=1 SV=3

C1QC_HUMAN

Complement C1q subcomponent subunit C OS=Homo sapiens
GN=C1QC PE=1 SV=3

AMBP_HUMAN

Protein AMBP OS=Homo sapiens GN=AMBP PE=1 SV=1

RAB10_HUMAN

Ras-related protein Rab-10 OS=Homo sapiens GN=RAB10
PE=1 SV=1

CH60_HUMAN

60 kDa heat shock protein, mitochondrial OS=Homo sapiens
GN=HSPD1 PE=1 SV=2

KAIN_HUMAN

Kallistatin OS=Homo sapiens GN=SERPINA4 PE=1 SV=3

GTR3_HUMAN

Solute carrier family 2, facilitated glucose transporter member 3
OS=Homo sapiens GN=SLC2A3 PE=2 SV=1

PLEK_HUMAN
SAA4_HUMAN

Pleckstrin OS=Homo sapiens GN=PLEK PE=1 SV=3
Serum amyloid A-4 protein OS=Homo sapiens GN=SAA4 PE=1
SV=2

HS71L_HUMAN

Heat shock 70 kDa protein 1-like OS=Homo sapiens
GN=HSPA1L PE=1 SV=2

ZA2G_HUMAN

Zinc-alpha-2-glycoprotein OS=Homo sapiens GN=AZGP1
PE=1 SV=2

HV306_HUMAN

Ig heavy chain V-III region BUT OS=Homo sapiens PE=1 SV=1

ATPA_HUMAN

ATP synthase subunit alpha, mitochondrial OS=Homo sapiens
GN=ATP5A1 PE=1 SV=1

APOC2_HUMAN

Apolipoprotein C-II OS=Homo sapiens GN=APOC2 PE=1
SV=1

KLKB1_HUMAN

Plasma kallikrein OS=Homo sapiens GN=KLKB1 PE=1 SV=1

FA10_HUMAN

Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2

CPN2_HUMAN

Carboxypeptidase N subunit 2 OS=Homo sapiens GN=CPN2
PE=1 SV=3

HXK1_HUMAN

Hexokinase-1 OS=Homo sapiens GN=HK1 PE=1 SV=3

GNAI2_HUMAN

Guanine nucleotide-binding protein G(i) subunit alpha-2
OS=Homo sapiens GN=GNAI2 PE=1 SV=3
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PECA1_HUMAN

Platelet endothelial cell adhesion molecule OS=Homo sapiens
GN=PECAM1 PE=1 SV=1

ITB1_HUMAN

Integrin beta-1 OS=Homo sapiens GN=ITGB1 PE=1 SV=2

BIN2_HUMAN

Bridging integrator 2 OS=Homo sapiens GN=BIN2 PE=1 SV=3

URP2_HUMAN

Fermitin family homolog 3 OS=Homo sapiens GN=FERMT3
PE=1 SV=1

FHR1_HUMAN

Complement factor H-related protein 1 OS=Homo sapiens
GN=CFHR1 PE=1 SV=2

K2C4_HUMAN

Keratin, type II cytoskeletal 4 OS=Homo sapiens GN=KRT4
PE=1 SV=4

KV301_HUMAN

Ig kappa chain V-III region B6 OS=Homo sapiens PE=1 SV=1

KV118_HUMAN

Ig kappa chain V-I region WEA OS=Homo sapiens PE=1 SV=1

KV105_HUMAN

Ig kappa chain V-I region DEE OS=Homo sapiens PE=1 SV=1

KV121_HUMAN

Ig kappa chain V-I region Ni OS=Homo sapiens PE=1 SV=1

KV106_HUMAN

Ig kappa chain V-I region EU OS=Homo sapiens PE=1 SV=1

LV302_HUMAN

Ig lambda chain V-III region LOI OS=Homo sapiens PE=1
SV=1

APOH_HUMAN

Beta-2-glycoprotein 1 OS=Homo sapiens GN=APOH PE=1
SV=3

TETN_HUMAN

Tetranectin OS=Homo sapiens GN=CLEC3B PE=1 SV=3

CD36_HUMAN

Platelet glycoprotein 4 OS=Homo sapiens GN=CD36 PE=1
SV=2

FBLN1_HUMAN
FCN3_HUMAN
HV320_HUMAN

Fibulin-1 OS=Homo sapiens GN=FBLN1 PE=1 SV=4
Ficolin-3 OS=Homo sapiens GN=FCN3 PE=1 SV=2
Ig heavy chain V-III region GAL OS=Homo sapiens PE=1
SV=1

C1QA_HUMAN

Complement C1q subcomponent subunit A OS=Homo sapiens
GN=C1QA PE=1 SV=2

LV106_HUMAN

Ig lambda chain V-I region WAH OS=Homo sapiens PE=1
SV=1

PROF1_HUMAN
RAP1B_HUMAN

Profilin-1 OS=Homo sapiens GN=PFN1 PE=1 SV=2
Ras-related protein Rap-1b OS=Homo sapiens GN=RAP1B
PE=1 SV=1
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RTN4_HUMAN

Reticulon-4 OS=Homo sapiens GN=RTN4 PE=1 SV=2

COF1_HUMAN
MDHM_HUMAN

Cofilin-1 OS=Homo sapiens GN=CFL1 PE=1 SV=3
Malate dehydrogenase, mitochondrial OS=Homo sapiens
GN=MDH2 PE=1 SV=3

ADT2_HUMAN

ADP/ATP translocase 2 OS=Homo sapiens GN=SLC25A5
PE=1 SV=7

AT5F1_HUMAN

ATP synthase F(0) complex subunit B1, mitochondrial
OS=Homo sapiens GN=ATP5F1 PE=1 SV=2

KV309_HUMAN

Ig kappa chain V-III region VG (Fragment) OS=Homo sapiens
PE=1 SV=1

MBL2_HUMAN

Mannose-binding protein C OS=Homo sapiens GN=MBL2
PE=1 SV=2

RB27B_HUMAN

Ras-related protein Rab-27B OS=Homo sapiens GN=RAB27B
PE=1 SV=4

VDAC2_HUMAN

Voltage-dependent anion-selective channel protein 2 OS=Homo
sapiens GN=VDAC2 PE=1 SV=2

CKLF5_HUMAN

CKLF-like MARVEL transmembrane domain-containing
protein 5 OS=Homo sapiens GN=CMTM5 PE=1 SV=2

LYSC_HUMAN

Lysozyme C OS=Homo sapiens GN=LYZ PE=1 SV=1

THAS_HUMAN

Thromboxane-A synthase OS=Homo sapiens GN=TBXAS1
PE=1 SV=3

CISY_HUMAN

Citrate synthase, mitochondrial OS=Homo sapiens GN=CS
PE=1 SV=2

TAGL2_HUMAN

Transgelin-2 OS=Homo sapiens GN=TAGLN2 PE=1 SV=3

COR1C_HUMAN

Coronin-1C OS=Homo sapiens GN=CORO1C PE=1 SV=1

CBPN_HUMAN

Carboxypeptidase N catalytic chain OS=Homo sapiens
GN=CPN1 PE=1 SV=1

ZYX_HUMAN
CAP1_HUMAN

Zyxin OS=Homo sapiens GN=ZYX PE=1 SV=1
Adenylyl cyclase-associated protein 1 OS=Homo sapiens
GN=CAP1 PE=1 SV=5

GBG5_HUMAN

Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit
gamma-5 OS=Homo sapiens GN=GNG5 PE=1 SV=3

PGRP2_HUMAN

N-acetylmuramoyl-L-alanine amidase OS=Homo sapiens
GN=PGLYRP2 PE=1 SV=1

INF2_HUMAN

Inverted formin-2 OS=Homo sapiens GN=INF2 PE=1 SV=2
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SEPP1_HUMAN

Selenoprotein P OS=Homo sapiens GN=SEPP1 PE=1 SV=3

LYAM3_HUMAN
LCAT_HUMAN

P-selectin OS=Homo sapiens GN=SELP PE=1 SV=3
Phosphatidylcholine-sterol acyltransferase OS=Homo sapiens
GN=LCAT PE=1 SV=1

COR1A_HUMAN

Coronin-1A OS=Homo sapiens GN=CORO1A PE=1 SV=4

ALS_HUMAN

Insulin-like growth factor-binding protein complex acid labile
subunit OS=Homo sapiens GN=IGFALS PE=1 SV=1

MPCP_HUMAN

Phosphate carrier protein, mitochondrial OS=Homo sapiens
GN=SLC25A3 PE=1 SV=2

CO8G_HUMAN

Complement component C8 gamma chain OS=Homo sapiens
GN=C8G PE=1 SV=3

CSRP1_HUMAN

Cysteine and glycine-rich protein 1 OS=Homo sapiens
GN=CSRP1 PE=1 SV=3

CAZA1_HUMAN

F-actin-capping protein subunit alpha-1 OS=Homo sapiens
GN=CAPZA1 PE=1 SV=3
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Appendix C: List of proteins identified in PCCF isolated using tandem
immunoaffinity method from plasma of patients with Gleason score 6.
Accession

Description

#Peptides

P01834|IGKC_HUMAN

Ig kappa chain C region OS=Homo
sapiens GN=IGKC PE=1 SV=1

7

P01834|IGKC_HUMAN

Ig kappa chain C region OS=Homo
sapiens GN=IGKC PE=1 SV=1

8

P01834|IGKC_HUMAN

Ig kappa chain C region OS=Homo
sapiens GN=IGKC PE=1 SV=1

12

P02768|ALBU_HUMAN

Serum albumin OS=Homo sapiens
GN=ALB PE=1 SV=2

57

P02768|ALBU_HUMAN

Serum albumin OS=Homo sapiens
GN=ALB PE=1 SV=2

60

P02768|ALBU_HUMAN
P0CG05|LAC2_HUMAN

P0CG06|LAC3_HUMAN

P01857|IGHG1_HUMAN

P01857|IGHG1_HUMAN

Serum albumin OS=Homo sapiens
GN=ALB PE=1 SV=2
Ig lambda-2 chain C regions
OS=Homo sapiens GN=IGLC2
PE=1 SV=1
Ig lambda-3 chain C regions
OS=Homo sapiens GN=IGLC3
PE=1 SV=1
Ig gamma-1 chain C region
OS=Homo sapiens GN=IGHG1
PE=1 SV=1
Ig gamma-1 chain C region
OS=Homo sapiens GN=IGHG1
PE=1 SV=1

60
5

5

24

29

P13645|K1C10_HUMAN

Keratin, type I cytoskeletal 10
OS=Homo sapiens GN=KRT10
PE=1 SV=6

33

P13645|K1C10_HUMAN

Keratin, type I cytoskeletal 10
OS=Homo sapiens GN=KRT10
PE=1 SV=6

31

P01857|IGHG1_HUMAN

P01859|IGHG2_HUMAN

Ig gamma-1 chain C region
OS=Homo sapiens GN=IGHG1
PE=1 SV=1
Ig gamma-2 chain C region
OS=Homo sapiens GN=IGHG2
PE=1 SV=2

18

19

P35908|K22E_HUMAN

Keratin, type II cytoskeletal 2
epidermal OS=Homo sapiens
GN=KRT2 PE=1 SV=2

28

P01859|IGHG2_HUMAN

Ig gamma-2 chain C region
OS=Homo sapiens GN=IGHG2
PE=1 SV=2

18

101

P01861|IGHG4_HUMAN

P01860|IGHG3_HUMAN

P04264|K2C1_HUMAN

P02763|A1AG1_HUMAN

P01861|IGHG4_HUMAN

Ig gamma-4 chain C region
OS=Homo sapiens GN=IGHG4
PE=1 SV=1
Ig gamma-3 chain C region
OS=Homo sapiens GN=IGHG3
PE=1 SV=2
Keratin, type II cytoskeletal 1
OS=Homo sapiens GN=KRT1 PE=1
SV=6
Alpha-1-acid glycoprotein 1
OS=Homo sapiens GN=ORM1
PE=1 SV=1
Ig gamma-4 chain C region
OS=Homo sapiens GN=IGHG4
PE=1 SV=1

17

17

32

7

14

P13645|K1C10_HUMAN

Keratin, type I cytoskeletal 10
OS=Homo sapiens GN=KRT10
PE=1 SV=6

22

P35527|K1C9_HUMAN

Keratin, type I cytoskeletal 9
OS=Homo sapiens GN=KRT9 PE=1
SV=3

24

P04264|K2C1_HUMAN

Keratin, type II cytoskeletal 1
OS=Homo sapiens GN=KRT1 PE=1
SV=6

27

P04206|KV307_HUMAN

Ig kappa chain V-III region GOL
OS=Homo sapiens PE=1 SV=1

3

P02452|CO1A1_HUMAN

Collagen alpha-1(I) chain OS=Homo
sapiens GN=COL1A1 PE=1 SV=5

133

P80748|LV302_HUMAN

Ig lambda chain V-III region LOI
OS=Homo sapiens PE=1 SV=1

3

B9A064|IGLL5_HUMAN

Immunoglobulin lambda-like
polypeptide 5 OS=Homo sapiens
GN=IGLL5 PE=2 SV=2

6

P02763|A1AG1_HUMAN

Alpha-1-acid glycoprotein 1
OS=Homo sapiens GN=ORM1
PE=1 SV=1

6

P04264|K2C1_HUMAN

Keratin, type II cytoskeletal 1
OS=Homo sapiens GN=KRT1 PE=1
SV=6

20

P35908|K22E_HUMAN

Keratin, type II cytoskeletal 2
epidermal OS=Homo sapiens
GN=KRT2 PE=1 SV=2

20

P81605|DCD_HUMAN

Dermcidin OS=Homo sapiens
GN=DCD PE=1 SV=2

2
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P01859|IGHG2_HUMAN

P01860|IGHG3_HUMAN

P01860|IGHG3_HUMAN
P02452|CO1A1_HUMAN
P0CG05|LAC2_HUMAN

P0CG06|LAC3_HUMAN

Ig gamma-2 chain C region
OS=Homo sapiens GN=IGHG2
PE=1 SV=2
Ig gamma-3 chain C region
OS=Homo sapiens GN=IGHG3
PE=1 SV=2
Ig gamma-3 chain C region
OS=Homo sapiens GN=IGHG3
PE=1 SV=2
Collagen alpha-1(I) chain OS=Homo
sapiens GN=COL1A1 PE=1 SV=5
Ig lambda-2 chain C regions
OS=Homo sapiens GN=IGLC2
PE=1 SV=1
Ig lambda-3 chain C regions
OS=Homo sapiens GN=IGLC3
PE=1 SV=1

16

16

18
92
3

3

P13647|K2C5_HUMAN

Keratin, type II cytoskeletal 5
OS=Homo sapiens GN=KRT5 PE=1
SV=3

19

P04206|KV307_HUMAN

Ig kappa chain V-III region GOL
OS=Homo sapiens PE=1 SV=1

2

P02452|CO1A1_HUMAN

Collagen alpha-1(I) chain OS=Homo
sapiens GN=COL1A1 PE=1 SV=5

82

P08123|CO1A2_HUMAN

Collagen alpha-2(I) chain OS=Homo
sapiens GN=COL1A2 PE=1 SV=7

57

P02452|CO1A1_HUMAN

Collagen alpha-1(I) chain OS=Homo
sapiens GN=COL1A1 PE=1 SV=5

64

P08123|CO1A2_HUMAN
P35527|K1C9_HUMAN
P08123|CO1A2_HUMAN

Collagen alpha-2(I) chain OS=Homo
sapiens GN=COL1A2 PE=1 SV=7
Keratin, type I cytoskeletal 9
OS=Homo sapiens GN=KRT9 PE=1
SV=3
Collagen alpha-2(I) chain OS=Homo
sapiens GN=COL1A2 PE=1 SV=7

80
15
66

P01598|KV106_HUMAN

Ig kappa chain V-I region EU
OS=Homo sapiens PE=1 SV=1

2

B9A064|IGLL5_HUMAN

Immunoglobulin lambda-like
polypeptide 5 OS=Homo sapiens
GN=IGLL5 PE=2 SV=2

5

P02763|A1AG1_HUMAN

Alpha-1-acid glycoprotein 1
OS=Homo sapiens GN=ORM1
PE=1 SV=1

5

103

P02533|K1C14_HUMAN

Keratin, type I cytoskeletal 14
OS=Homo sapiens GN=KRT14
PE=1 SV=4

12

P07478|TRY2_HUMAN

Trypsin-2 OS=Homo sapiens
GN=PRSS2 PE=1 SV=1

20

P02647|APOA1_HUMAN
P02461|CO3A1_HUMAN
P08123|CO1A2_HUMAN

Apolipoprotein A-I OS=Homo
sapiens GN=APOA1 PE=1 SV=1
Collagen alpha-1(III) chain
OS=Homo sapiens GN=COL3A1
PE=1 SV=4
Collagen alpha-2(I) chain OS=Homo
sapiens GN=COL1A2 PE=1 SV=7

5
37
34

P04433|KV309_HUMAN

Ig kappa chain V-III region VG
(Fragment) OS=Homo sapiens PE=1
SV=1

2

P04433|KV309_HUMAN

Ig kappa chain V-III region VG
(Fragment) OS=Homo sapiens PE=1
SV=1

2

P19652|A1AG2_HUMAN
P35030|TRY3_HUMAN
P02458|CO2A1_HUMAN

P02461|CO3A1_HUMAN
P81605|DCD_HUMAN

Alpha-1-acid glycoprotein 2
OS=Homo sapiens GN=ORM2
PE=1 SV=2
Trypsin-3 OS=Homo sapiens
GN=PRSS3 PE=1 SV=2
Collagen alpha-1(II) chain
OS=Homo sapiens GN=COL2A1
PE=1 SV=3
Collagen alpha-1(III) chain
OS=Homo sapiens GN=COL3A1
PE=1 SV=4
Dermcidin OS=Homo sapiens
GN=DCD PE=1 SV=2

4
8
19

44
2

B9A064|IGLL5_HUMAN

Immunoglobulin lambda-like
polypeptide 5 OS=Homo sapiens
GN=IGLL5 PE=2 SV=2

4

P35527|K1C9_HUMAN

Keratin, type I cytoskeletal 9
OS=Homo sapiens GN=KRT9 PE=1
SV=3

10

P13647|K2C5_HUMAN

Keratin, type II cytoskeletal 5
OS=Homo sapiens GN=KRT5 PE=1
SV=3

12

P35030|TRY3_HUMAN

Trypsin-3 OS=Homo sapiens
GN=PRSS3 PE=1 SV=2

12

Q8NHM4|TRY6_HUMAN

Putative trypsin-6 OS=Homo
sapiens GN=TRY6 PE=5 SV=1

7

104

P01765|HV304_HUMAN

Ig heavy chain V-III region TIL
OS=Homo sapiens PE=1 SV=1

1

P01596|KV104_HUMAN

Ig kappa chain V-I region CAR
OS=Homo sapiens PE=1 SV=1

1

P01598|KV106_HUMAN

Ig kappa chain V-I region EU
OS=Homo sapiens PE=1 SV=1

1

P02787|TRFE_HUMAN

Serotransferrin OS=Homo sapiens
GN=TF PE=1 SV=3

9

P07477|TRY1_HUMAN

Trypsin-1 OS=Homo sapiens
GN=PRSS1 PE=1 SV=1

12

P02747|C1QC_HUMAN

Complement C1q subcomponent
subunit C OS=Homo sapiens
GN=C1QC PE=1 SV=3

3

P01766|HV305_HUMAN

Ig heavy chain V-III region BRO
OS=Homo sapiens PE=1 SV=1

5

P01766|HV305_HUMAN

Ig heavy chain V-III region BRO
OS=Homo sapiens PE=1 SV=1

1

P01774|HV313_HUMAN

Ig heavy chain V-III region POM
OS=Homo sapiens PE=1 SV=1

1

P01774|HV313_HUMAN

Ig heavy chain V-III region POM
OS=Homo sapiens PE=1 SV=1

1

P01777|HV316_HUMAN

Ig heavy chain V-III region TEI
OS=Homo sapiens PE=1 SV=1

3

P01762|HV301_HUMAN

Ig heavy chain V-III region TRO
OS=Homo sapiens PE=1 SV=1

1

P01762|HV301_HUMAN

Ig heavy chain V-III region TRO
OS=Homo sapiens PE=1 SV=1

1

P01779|HV318_HUMAN

Ig heavy chain V-III region TUR
OS=Homo sapiens PE=1 SV=1

1

P01764|HV303_HUMAN

Ig heavy chain V-III region VH26
OS=Homo sapiens PE=1 SV=1

1

P01776|HV315_HUMAN

Ig heavy chain V-III region WAS
OS=Homo sapiens PE=1 SV=1

1

P04433|KV309_HUMAN

Ig kappa chain V-III region VG
(Fragment) OS=Homo sapiens PE=1
SV=1

1

P07477|TRY1_HUMAN
P02461|CO3A1_HUMAN

Trypsin-1 OS=Homo sapiens
GN=PRSS1 PE=1 SV=1
Collagen alpha-1(III) chain
OS=Homo sapiens GN=COL3A1
PE=1 SV=4

6
30

105

P02746|C1QB_HUMAN

Complement C1q subcomponent
subunit B OS=Homo sapiens
GN=C1QB PE=1 SV=3

4

P00738|HPT_HUMAN

Haptoglobin OS=Homo sapiens
GN=HP PE=1 SV=1

6

P01593|KV101_HUMAN

Ig kappa chain V-I region AG
OS=Homo sapiens PE=1 SV=1

1

P07478|TRY2_HUMAN

Trypsin-2 OS=Homo sapiens
GN=PRSS2 PE=1 SV=1

10

P01876|IGHA1_HUMAN

Ig alpha-1 chain C region OS=Homo
sapiens GN=IGHA1 PE=1 SV=2

4

P01876|IGHA1_HUMAN

Ig alpha-1 chain C region OS=Homo
sapiens GN=IGHA1 PE=1 SV=2

4

P01876|IGHA1_HUMAN

Ig alpha-1 chain C region OS=Homo
sapiens GN=IGHA1 PE=1 SV=2

4

P01871|IGHM_HUMAN

Ig mu chain C region OS=Homo
sapiens GN=IGHM PE=1 SV=3

6

P35908|K22E_HUMAN

Keratin, type II cytoskeletal 2
epidermal OS=Homo sapiens
GN=KRT2 PE=1 SV=2

8

P19652|A1AG2_HUMAN
P02647|APOA1_HUMAN
P02458|CO2A1_HUMAN

P02461|CO3A1_HUMAN

P02462|CO4A1_HUMAN

Alpha-1-acid glycoprotein 2
OS=Homo sapiens GN=ORM2
PE=1 SV=2
Apolipoprotein A-I OS=Homo
sapiens GN=APOA1 PE=1 SV=1
Collagen alpha-1(II) chain
OS=Homo sapiens GN=COL2A1
PE=1 SV=3
Collagen alpha-1(III) chain
OS=Homo sapiens GN=COL3A1
PE=1 SV=4
Collagen alpha-1(IV) chain
OS=Homo sapiens GN=COL4A1
PE=1 SV=3

3
3
23

18

9

P02747|C1QC_HUMAN

Complement C1q subcomponent
subunit C OS=Homo sapiens
GN=C1QC PE=1 SV=3

2

P01617|KV204_HUMAN

Ig kappa chain V-II region TEW
OS=Homo sapiens PE=1 SV=1

1

P02768|ALBU_HUMAN

Serum albumin OS=Homo sapiens
GN=ALB PE=1 SV=2

6

P01614|KV201_HUMAN

Ig kappa chain V-II region Cum
OS=Homo sapiens PE=1 SV=1

1

106

P01614|KV201_HUMAN

Ig kappa chain V-II region Cum
OS=Homo sapiens PE=1 SV=1

1

P06309|KV205_HUMAN

Ig kappa chain V-II region GM607
(Fragment) OS=Homo sapiens PE=4
SV=1

1

P13645|K1C10_HUMAN

Keratin, type I cytoskeletal 10
OS=Homo sapiens GN=KRT10
PE=1 SV=6

4

P02458|CO2A1_HUMAN

P05997|CO5A2_HUMAN
P81605|DCD_HUMAN

Collagen alpha-1(II) chain
OS=Homo sapiens GN=COL2A1
PE=1 SV=3
Collagen alpha-2(V) chain
OS=Homo sapiens GN=COL5A2
PE=1 SV=3
Dermcidin OS=Homo sapiens
GN=DCD PE=1 SV=2

14

15
1

P01742|HV101_HUMAN

Ig heavy chain V-I region EU
OS=Homo sapiens PE=1 SV=1

1

P01742|HV101_HUMAN

Ig heavy chain V-I region EU
OS=Homo sapiens PE=1 SV=1

1

P01743|HV102_HUMAN

Ig heavy chain V-I region HG3
OS=Homo sapiens PE=4 SV=1

1

P06326|HV107_HUMAN

Ig heavy chain V-I region Mot
OS=Homo sapiens PE=1 SV=1

1

P01761|HV106_HUMAN

Ig heavy chain V-I region SIE
OS=Homo sapiens PE=1 SV=1

1

P23083|HV103_HUMAN

Ig heavy chain V-I region V35
OS=Homo sapiens PE=1 SV=1

1

P23083|HV103_HUMAN

Ig heavy chain V-I region V35
OS=Homo sapiens PE=1 SV=1

1

P06310|KV206_HUMAN

Ig kappa chain V-II region RPMI
6410 OS=Homo sapiens PE=4 SV=1

1

P06310|KV206_HUMAN

Ig kappa chain V-II region RPMI
6410 OS=Homo sapiens PE=4 SV=1

1

P04259|K2C6B_HUMAN

Keratin, type II cytoskeletal 6B
OS=Homo sapiens GN=KRT6B
PE=1 SV=5

5

A6NJS3|IV1U1_HUMAN

Putative V-set and immunoglobulin
domain-containing-like protein
IGHV1OR21-1 OS=Homo sapiens
GN=IGHV1OR21-1 PE=5 SV=1

1

107

O60902|SHOX2_HUMAN

Short stature homeobox protein 2
OS=Homo sapiens GN=SHOX2
PE=2 SV=4

1

P04632|CPNS1_HUMAN

Calpain small subunit 1 OS=Homo
sapiens GN=CAPNS1 PE=1 SV=1

1

Q8NFW1|COMA1_HUMAN

Collagen alpha-1(XXII) chain
OS=Homo sapiens GN=COL22A1
PE=1 SV=2

7

P25940|CO5A3_HUMAN

Collagen alpha-3(V) chain
OS=Homo sapiens GN=COL5A3
PE=1 SV=3

7

Q5VWW1|C1QL3_HUMAN

Complement C1q-like protein 3
OS=Homo sapiens GN=C1QL3
PE=2 SV=1

1

Q5VWW1|C1QL3_HUMAN

Complement C1q-like protein 3
OS=Homo sapiens GN=C1QL3
PE=2 SV=1

1

Q5VWW1|C1QL3_HUMAN

Complement C1q-like protein 3
OS=Homo sapiens GN=C1QL3
PE=2 SV=1

1

Q7Z794|K2C1B_HUMAN

Keratin, type II cytoskeletal 1b
OS=Homo sapiens GN=KRT77
PE=2 SV=3

5

P04259|K2C6B_HUMAN

Keratin, type II cytoskeletal 6B
OS=Homo sapiens GN=KRT6B
PE=1 SV=5

4

P01625|KV402_HUMAN

Ig kappa chain V-IV region Len
OS=Homo sapiens PE=1 SV=2

1

P08727|K1C19_HUMAN

Keratin, type I cytoskeletal 19
OS=Homo sapiens GN=KRT19
PE=1 SV=4

4

Q7Z3Y8|K1C27_HUMAN

Keratin, type I cytoskeletal 27
OS=Homo sapiens GN=KRT27
PE=1 SV=2

5

P06312|KV401_HUMAN

Ig kappa chain V-IV region
(Fragment) OS=Homo sapiens
GN=IGKV4-1 PE=4 SV=1

1

P06313|KV403_HUMAN

Ig kappa chain V-IV region JI
OS=Homo sapiens PE=4 SV=1

1

Q86Y46|K2C73_HUMAN

Keratin, type II cytoskeletal 73
OS=Homo sapiens GN=KRT73
PE=1 SV=1

4

108

Q86Y46|K2C73_HUMAN

Keratin, type II cytoskeletal 73
OS=Homo sapiens GN=KRT73
PE=1 SV=1

4

Q7RTS7|K2C74_HUMAN

Keratin, type II cytoskeletal 74
OS=Homo sapiens GN=KRT74
PE=1 SV=2

4

O00570|SOX1_HUMAN
P35030|TRY3_HUMAN

Transcription factor SOX-1
OS=Homo sapiens GN=SOX1 PE=1
SV=2
Trypsin-3 OS=Homo sapiens
GN=PRSS3 PE=1 SV=2

1
5

Q9NY12|GAR1_HUMAN

H/ACA ribonucleoprotein complex
subunit 1 OS=Homo sapiens
GN=GAR1 PE=1 SV=1

1

Q7Z794|K2C1B_HUMAN

Keratin, type II cytoskeletal 1b
OS=Homo sapiens GN=KRT77
PE=2 SV=3

2

Q9Y2Z2|MTO1_HUMAN

Protein MTO1 homolog,
mitochondrial OS=Homo sapiens
GN=MTO1 PE=1 SV=2

1

P35247|SFTPD_HUMAN

Pulmonary surfactant-associated
protein D OS=Homo sapiens
GN=SFTPD PE=1 SV=3

1

Q17RW2|COOA1_HUMAN

Collagen alpha-1(XXIV) chain
OS=Homo sapiens GN=COL24A1
PE=2 SV=2

6

P05997|CO5A2_HUMAN

P53420|CO4A4_HUMAN
P02675|FIBB_HUMAN

P13647|K2C5_HUMAN

Collagen alpha-2(V) chain
OS=Homo sapiens GN=COL5A2
PE=1 SV=3
Collagen alpha-4(IV) chain
OS=Homo sapiens GN=COL4A4
PE=1 SV=3
Fibrinogen beta chain OS=Homo
sapiens GN=FGB PE=1 SV=2
Keratin, type II cytoskeletal 5
OS=Homo sapiens GN=KRT5 PE=1
SV=3

12

5
3

3

Macrophage receptor MARCO
Q9UEW3|MARCO_HUMAN OS=Homo sapiens GN=MARCO
PE=1 SV=1

1

Apolipoprotein A-I OS=Homo
sapiens GN=APOA1 PE=1 SV=1

1

P02647|APOA1_HUMAN

109

P13942|COBA2_HUMAN

P25940|CO5A3_HUMAN

Collagen alpha-2(XI) chain
OS=Homo sapiens GN=COL11A2
PE=1 SV=5
Collagen alpha-3(V) chain
OS=Homo sapiens GN=COL5A3
PE=1 SV=3

5

5

Q8N136|DAW1_HUMAN

Dynein assembly factor with WDR
repeat domains 1 OS=Homo sapiens
GN=DAW1 PE=1 SV=1

1

P15814|IGLL1_HUMAN

Immunoglobulin lambda-like
polypeptide 1 OS=Homo sapiens
GN=IGLL1 PE=1 SV=1

1

P02787|TRFE_HUMAN

Serotransferrin OS=Homo sapiens
GN=TF PE=1 SV=3

2

P02787|TRFE_HUMAN
Q99442|SEC62_HUMAN

Serotransferrin OS=Homo sapiens
GN=TF PE=1 SV=3
Translocation protein SEC62
OS=Homo sapiens GN=SEC62
PE=1 SV=1

2
1

B7Z1M9|C2D4D_HUMAN

C2 calcium-dependent domaincontaining protein 4D OS=Homo
sapiens GN=C2CD4D PE=2 SV=2

1

B7Z1M9|C2D4D_HUMAN

C2 calcium-dependent domaincontaining protein 4D OS=Homo
sapiens GN=C2CD4D PE=2 SV=2

1

Q6PK04|CC137_HUMAN

Coiled-coil domain-containing
protein 137 OS=Homo sapiens
GN=CCDC137 PE=1 SV=1

1

Q6PK04|CC137_HUMAN

Coiled-coil domain-containing
protein 137 OS=Homo sapiens
GN=CCDC137 PE=1 SV=1

1

P20908|CO5A1_HUMAN

P12107|COBA1_HUMAN

Q5TAT6|CODA1_HUMAN

Q14055|CO9A2_HUMAN

P13942|COBA2_HUMAN

Collagen alpha-1(V) chain
OS=Homo sapiens GN=COL5A1
PE=1 SV=3
Collagen alpha-1(XI) chain
OS=Homo sapiens GN=COL11A1
PE=1 SV=4
Collagen alpha-1(XIII) chain
OS=Homo sapiens GN=COL13A1
PE=1 SV=1
Collagen alpha-2(IX) chain
OS=Homo sapiens GN=COL9A2
PE=1 SV=2
Collagen alpha-2(XI) chain
OS=Homo sapiens GN=COL11A2
PE=1 SV=5

4

3

1

1

4

110

P25940|CO5A3_HUMAN
Q9H461|FZD8_HUMAN

Collagen alpha-3(V) chain
OS=Homo sapiens GN=COL5A3
PE=1 SV=3
Frizzled-8 OS=Homo sapiens
GN=FZD8 PE=1 SV=1

4
1

Q7Z2K8|GRIN1_HUMAN

G protein-regulated inducer of
neurite outgrowth 1 OS=Homo
sapiens GN=GPRIN1 PE=2 SV=2

1

O60658|PDE8A_HUMAN

High affinity cAMP-specific and
IBMX-insensitive 3',5'-cyclic
phosphodiesterase 8A OS=Homo
sapiens GN=PDE8A PE=1 SV=2

1

Q9UH92|MLX_HUMAN

Max-like protein X OS=Homo
sapiens GN=MLX PE=1 SV=

1

Q8IXF0|NPAS3_HUMAN

Neuronal PAS domain-containing
protein 3 OS=Homo sapiens
GN=NPAS3 PE=2 SV=1

1

Q9H340|O51B6_HUMAN

Olfactory receptor 51B6 OS=Homo
sapiens GN=OR51B6 PE=2 SV=2

1

Q5T750|XP32_HUMAN

Skin-specific protein 32 OS=Homo
sapiens GN=XP32 PE=1 SV=1

1

Q5T750|XP32_HUMAN

Skin-specific protein 32 OS=Homo
sapiens GN=XP32 PE=1 SV=1

1

Q6UWP8|SBSN_HUMAN

Suprabasin OS=Homo sapiens
GN=SBSN PE=2 SV=2

1

Q7L2R6|ZN765_HUMAN
P01009|A1AT_HUMAN
P01023|A2MG_HUMAN

Zinc finger protein 765 OS=Homo
sapiens GN=ZNF765 PE=2 SV=2
Alpha-1-antitrypsin OS=Homo
sapiens GN=SERPINA1 PE=1
SV=3
Alpha-2-macroglobulin OS=Homo
sapiens GN=A2M PE=1 SV=3

1
1
2

A9YTQ3|AHRR_HUMAN

Aryl hydrocarbon receptor repressor
OS=Homo sapiens GN=AHRR
PE=2 SV=3

1

Q12791|KCMA1_HUMAN

Calcium-activated potassium
channel subunit alpha-1 OS=Homo
sapiens GN=KCNMA1 PE=1 SV=2

1

P12107|COBA1_HUMAN

P12107|COBA1_HUMAN

Collagen alpha-1(XI) chain
OS=Homo sapiens GN=COL11A1
PE=1 SV=4
Collagen alpha-1(XI) chain
OS=Homo sapiens GN=COL11A1
PE=1 SV=4

3

2

111

P25067|CO8A2_HUMAN

P13942|COBA2_HUMAN
P02675|FIBB_HUMAN

Collagen alpha-2(VIII) chain
OS=Homo sapiens GN=COL8A2
PE=1 SV=2
Collagen alpha-2(XI) chain
OS=Homo sapiens GN=COL11A2
PE=1 SV=5
Fibrinogen beta chain OS=Homo
sapiens GN=FGB PE=1 SV=2

1

2
1

P78415|IRX3_HUMAN

Iroquois-class homeodomain protein
IRX-3 OS=Homo sapiens GN=IRX3
PE=2 SV=3

1

Q5VZ66|JKIP3_HUMAN

Janus kinase and microtubuleinteracting protein 3 OS=Homo
sapiens GN=JAKMIP3 PE=2 SV=2

1

Q7Z478|DHX29_HUMAN

ATP-dependent RNA helicase
DHX29 OS=Homo sapiens
GN=DHX29 PE=1 SV=2

1

P20908|CO5A1_HUMAN

P29400|CO4A5_HUMAN
P01024|CO3_HUMAN

Collagen alpha-1(V) chain
OS=Homo sapiens GN=COL5A1
PE=1 SV=3
Collagen alpha-5(IV) chain
OS=Homo sapiens GN=COL4A5
PE=1 SV=2
Complement C3 OS=Homo sapiens
GN=C3 PE=1 SV=2

1

1
1

P02671|FIBA_HUMAN

Fibrinogen alpha chain OS=Homo
sapiens GN=FGA PE=1 SV=2

1

Q96PE1|GP124_HUMAN

G-protein coupled receptor 124
OS=Homo sapiens GN=GPR124
PE=1 SV=2

1

Q5T764|IFT1B_HUMAN

Interferon-induced protein with
tetratricopeptide repeats 1B
OS=Homo sapiens GN=IFIT1B
PE=2 SV=1

1

Q5TCX8|M3KL4_HUMAN

Mitogen-activated protein kinase
kinase kinase MLK4 OS=Homo
sapiens GN=MLK4 PE=1 SV=1

1

O95428|PPN_HUMAN

Papilin OS=Homo sapiens
GN=PAPLN PE=2 SV=4

1

Q6ZRV2|FA83H_HUMAN
Q02388|CO7A1_HUMAN

Protein FAM83H OS=Homo sapiens
GN=FAM83H PE=1 SV=3
Collagen alpha-1(VII) chain
OS=Homo sapiens GN=COL7A1
PE=1 SV=2

1
1

112

Q5D862|FILA2_HUMAN

Filaggrin-2 OS=Homo sapiens
GN=FLG2 PE=1 SV=1

1

Q8WZ42|TITIN_HUMAN

Titin OS=Homo sapiens GN=TTN
PE=1 SV=4

6

Q8WZ42|TITIN_HUMAN

Titin OS=Homo sapiens GN=TTN
PE=1 SV=4

1

Q5THJ4|VP13D_HUMAN

Vacuolar protein sorting-associated
protein 13D OS=Homo sapiens
GN=VPS13D PE=1 SV=1

1

Appendix D: List of proteins identified in PCCF isolated using tandem
immunoaffinity method from plasma of patients with Gleason score 8.
Accession

Description

Number of
Peptides

P02768|ALBU_HUMAN

Serum albumin OS=Homo sapiens
GN=ALB PE=1 SV=2

56

P02452|CO1A1_HUMAN

Collagen alpha-1(I) chain OS=Homo
sapiens GN=COL1A1 PE=1 SV=5

55

P08123|CO1A2_HUMAN
P13645|K1C10_HUMAN
P02461|CO3A1_HUMAN
P04264|K2C1_HUMAN
P01857|IGHG1_HUMAN
P02458|CO2A1_HUMAN
P01859|IGHG2_HUMAN
P08779|K1C16_HUMAN
P07478|TRY2_HUMAN

Collagen alpha-2(I) chain OS=Homo
sapiens GN=COL1A2 PE=1 SV=7
Keratin, type I cytoskeletal 10
OS=Homo sapiens GN=KRT10 PE=1
SV=6
Collagen alpha-1(III) chain OS=Homo
sapiens GN=COL3A1 PE=1 SV=4
Keratin, type II cytoskeletal 1
OS=Homo sapiens GN=KRT1 PE=1
SV=6
Ig gamma-1 chain C region OS=Homo
sapiens GN=IGHG1 PE=1 SV=1
Collagen alpha-1(II) chain OS=Homo
sapiens GN=COL2A1 PE=1 SV=3
Ig gamma-2 chain C region OS=Homo
sapiens GN=IGHG2 PE=1 SV=2
Keratin, type I cytoskeletal 16
OS=Homo sapiens GN=KRT16 PE=1
SV=4
Trypsin-2 OS=Homo sapiens
GN=PRSS2 PE=1 SV=1

48
31
31
25
18
18
14
12
12
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P35527|K1C9_HUMAN
P35030|TRY3_HUMAN
P01860|IGHG3_HUMAN
P02538|K2C6A_HUMAN

P35908|K22E_HUMAN

P04259|K2C6B_HUMAN

P13647|K2C5_HUMAN
P02787|TRFE_HUMAN
P01834|IGKC_HUMAN
Q86Y46|K2C73_HUMAN

Q04695|K1C17_HUMAN

P0CG06|LAC3_HUMAN

P19012|K1C15_HUMAN

P13646|K1C13_HUMAN

Q5XKE5|K2C79_HUMAN

Q7Z3Y7|K1C28_HUMAN

Keratin, type I cytoskeletal 9
OS=Homo sapiens GN=KRT9 PE=1
SV=3
Trypsin-3 OS=Homo sapiens
GN=PRSS3 PE=1 SV=2
Ig gamma-3 chain C region OS=Homo
sapiens GN=IGHG3 PE=1 SV=2
Keratin, type II cytoskeletal 6A
OS=Homo sapiens GN=KRT6A PE=1
SV=3
Keratin, type II cytoskeletal 2
epidermal OS=Homo sapiens
GN=KRT2 PE=1 SV=2
Keratin, type II cytoskeletal 6B
OS=Homo sapiens GN=KRT6B PE=1
SV=5
Keratin, type II cytoskeletal 5
OS=Homo sapiens GN=KRT5 PE=1
SV=3
Serotransferrin OS=Homo sapiens
GN=TF PE=1 SV=3
Ig kappa chain C region OS=Homo
sapiens GN=IGKC PE=1 SV=1
Keratin, type II cytoskeletal 73
OS=Homo sapiens GN=KRT73 PE=1
SV=1
Keratin, type I cytoskeletal 17
OS=Homo sapiens GN=KRT17 PE=1
SV=2
Ig lambda-3 chain C regions
OS=Homo sapiens GN=IGLC3 PE=1
SV=1
Keratin, type I cytoskeletal 15
OS=Homo sapiens GN=KRT15 PE=1
SV=3
Keratin, type I cytoskeletal 13
OS=Homo sapiens GN=KRT13 PE=1
SV=4
Keratin, type II cytoskeletal 79
OS=Homo sapiens GN=KRT79 PE=1
SV=2
Keratin, type I cytoskeletal 28
OS=Homo sapiens GN=KRT28 PE=1
SV=2

11
11
10
10

10

9

8
8
6
6

6

5

5

5

4

4
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Q7RTS7|K2C74_HUMAN

O95678|K2C75_HUMAN
Q86YZ3|HORN_HUMAN
Q8TF68|ZN384_HUMAN
P08727|K1C19_HUMAN
P01766|HV305_HUMAN
Q2M2I5|K1C24_HUMAN
P01777|HV316_HUMAN

Keratin, type II cytoskeletal 74
OS=Homo sapiens GN=KRT74 PE=1
SV=2
Keratin, type II cytoskeletal 75
OS=Homo sapiens GN=KRT75 PE=1
SV=2
Hornerin OS=Homo sapiens
GN=HRNR PE=1 SV=2
Zinc finger protein 384 OS=Homo
sapiens GN=ZNF384 PE=1 SV=2
Keratin, type I cytoskeletal 19
OS=Homo sapiens GN=KRT19 PE=1
SV=4
Ig heavy chain V-III region BRO
OS=Homo sapiens PE=1 SV=1
Keratin, type I cytoskeletal 24
OS=Homo sapiens GN=KRT24 PE=1
SV=1
Ig heavy chain V-III region TEI
OS=Homo sapiens PE=1 SV=1

4

4
4
3
3
2
2
1

Q8N1X5|YF001_HUMAN

Uncharacterized protein FLJ37310
OS=Homo sapiens PE=2 SV=1

1

P10599|THIO_HUMAN

Thioredoxin OS=Homo sapiens
GN=TXN PE=1 SV=3

1

P06309|KV205_HUMAN

Ig kappa chain V-II region GM607
(Fragment) OS=Homo sapiens PE=4
SV=1

1

P81605|DCD_HUMAN

Dermcidin OS=Homo sapiens
GN=DCD PE=1 SV=2

1

P56270|MAZ_HUMAN

P04433|KV309_HUMAN
P68871|HBB_HUMAN
P02042|HBD_HUMAN
P02100|HBE_HUMAN

Myc-associated zinc finger protein
OS=Homo sapiens GN=MAZ PE=1
SV=1
Ig kappa chain V-III region VG
(Fragment) OS=Homo sapiens PE=1
SV=1
Hemoglobin subunit beta OS=Homo
sapiens GN=HBB PE=1 SV=2
Hemoglobin subunit delta OS=Homo
sapiens GN=HBD PE=1 SV=2
Hemoglobin subunit epsilon
OS=Homo sapiens GN=HBE1 PE=1
SV=2

1

1
1
1
1
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P69891|HBG1_HUMAN

P69892|HBG2_HUMAN

P15814|IGLL1_HUMAN
Q9Y2T7|YBOX2_HUMAN
Q8IYT1|FA71A_HUMAN
P02763|A1AG1_HUMAN
P01009|A1AT_HUMAN

Hemoglobin subunit gamma-1
OS=Homo sapiens GN=HBG1 PE=1
SV=2
Hemoglobin subunit gamma-2
OS=Homo sapiens GN=HBG2 PE=1
SV=2
Immunoglobulin lambda-like
polypeptide 1 OS=Homo sapiens
GN=IGLL1 PE=1 SV=1
Y-box-binding protein 2 OS=Homo
sapiens GN=YBX2 PE=1 SV=2

1

1

1
1

Protein FAM71A OS=Homo sapiens
1
GN=FAM71A PE=2 SV=2
Alpha-1-acid glycoprotein 1
OS=Homo sapiens GN=ORM1 PE=1
1
SV=1
Alpha-1-antitrypsin OS=Homo sapiens
1
GN=SERPINA1 PE=1 SV=3

P02647|APOA1_HUMAN

Apolipoprotein A-I OS=Homo sapiens
GN=APOA1 PE=1 SV=1

1

P04899|GNAI2_HUMAN

Guanine nucleotide-binding protein
G(i) subunit alpha-2 OS=Homo
sapiens GN=GNAI2 PE=1 SV=3

1

O43525|KCNQ3_HUMAN

Potassium voltage-gated channel
subfamily KQT member 3 OS=Homo
sapiens GN=KCNQ3 PE=1 SV=2

1

P02812|PRB2_HUMAN

Basic salivary proline-rich protein 2
OS=Homo sapiens GN=PRB2 PE=1
SV=3

1

Q9P0G3|KLK14_HUMAN
P02533|K1C14_HUMAN

Q8N145|LGI3_HUMAN

P67809|YBOX1_HUMAN

Kallikrein-14 OS=Homo sapiens
GN=KLK14 PE=1 SV=2
Keratin, type I cytoskeletal 14
OS=Homo sapiens GN=KRT14 PE=1
SV=4
Leucine-rich repeat LGI family
member 3 OS=Homo sapiens
GN=LGI3 PE=2 SV=1
Nuclease-sensitive element-binding
protein 1 OS=Homo sapiens
GN=YBX1 PE=1 SV=3

1
1

1

1
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Q10571|MN1_HUMAN

Probable tumor suppressor protein
MN1 OS=Homo sapiens GN=MN1
PE=1 SV=3

1

Q16651|PRSS8_HUMAN

Prostasin OS=Homo sapiens
GN=PRSS8 PE=1 SV=1

1

Q6UWP8|SBSN_HUMAN
Q5TAT6|CODA1_HUMAN
P02671|FIBA_HUMAN

Suprabasin OS=Homo sapiens
GN=SBSN PE=2 SV=2
Collagen alpha-1(XIII) chain
OS=Homo sapiens GN=COL13A1
PE=1 SV=1
Fibrinogen alpha chain OS=Homo
sapiens GN=FGA PE=1 SV=2

1
1
1

O60763|USO1_HUMAN

General vesicular transport factor p115
OS=Homo sapiens GN=USO1 PE=1
1
SV=2

Q9UKX3|MYH13_HUMAN

Myosin-13 OS=Homo sapiens
GN=MYH13 PE=1 SV=2

1

Q96Q06|PLIN4_HUMAN

Perilipin-4 OS=Homo sapiens
GN=PLIN4 PE=2 SV=2

1

Q15283|RASA2_HUMAN

Ras GTPase-activating protein 2
OS=Homo sapiens GN=RASA2 PE=1
SV=3

1

P53420|CO4A4_HUMAN

Collagen alpha-4(IV) chain OS=Homo
sapiens GN=COL4A4 PE=1 SV=3

1

P01024|CO3_HUMAN

Complement C3 OS=Homo sapiens
GN=C3 PE=1 SV=2

1

Q9BZQ6|EDEM3_HUMAN

ER degradation-enhancing alphamannosidase-like protein 3 OS=Homo
sapiens GN=EDEM3 PE=1 SV=2

1

Q96PE1|GP124_HUMAN

G-protein coupled receptor 124
OS=Homo sapiens GN=GPR124
PE=1 SV=2

1

Q6ZRV2|FA83H_HUMAN

Protein FAM83H OS=Homo sapiens
GN=FAM83H PE=1 SV=3

1

H7BZ55|CROL3_HUMAN

Putative ciliary rootlet coiled-coil
protein-like 3 protein OS=Homo
sapiens PE=5 SV=2

1

Q9H2D6|TARA_HUMAN

TRIO and F-actin-binding protein
OS=Homo sapiens GN=TRIOBP
PE=1 SV=3

1
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Q562E7|WDR81_HUMAN

WD repeat-containing protein 81
OS=Homo sapiens GN=WDR81 PE=1 1
SV=2

Q12802|AKP13_HUMAN

A-kinase anchor protein 13 OS=Homo
sapiens GN=AKAP13 PE=1 SV=2

1

P08F94|PKHD1_HUMAN

Fibrocystin OS=Homo sapiens
GN=PKHD1 PE=1 SV=1

1

Q03164|KMT2A_HUMAN

Histone-lysine N-methyltransferase
2A OS=Homo sapiens GN=KMT2A
PE=1 SV=5

1

Q9UPA5|BSN_HUMAN

Protein bassoon OS=Homo sapiens
GN=BSN PE=2 SV=4

1
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